For non-commercial use only
PROTOCOL
An Open -Label, Ro llover Protocol for Patients Previously Enro lled in Takeda -Sponsored 
Ixazo mib Studies 
Ixazomib Rollover Study
Sponsor: Takeda Development Center Americas, Inc 
95 Hay den Avenue
Lexington, MA 02421 ,USA
Telephone: +1 (617) 679 -7000
Study Number: C16027
EudraCT Number: 2016-001681-28
Compound: Ixazo mib
Date: 03 June 2021 Amendment Number: 03
Amendment History:
Date Amendment NumberAmendment Type (for regional 
Europe purposes only) Region
30 June 2016 Initial Protocol Not applicable Global
23 March 2017 01 Substantial amendment Global
08 November 2017 02 Nonsubstantial amendment Local (Sweden)
03 June 2021 03 Substantial amendment Global
CONFIDENTIAL PROPERTY OF TAKEDA
This document is a confidential communication of Takeda. Acceptance of this document constitutes the agreement by 
the recipient that no information contained herein will be published or discl osed without written authorization from 
Takeda except to the extent necessary to obtain informed consent from those persons to whom the drug may be 
administered. Furthermore, the information is only meant for review and compliance by the recipient, his or her staff, 
and applicable institutional review committee and regulatory agencies to enable conduct of the study.
For non-commercial use only
Ixazomib
Study No. C16027 Page 2of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIAL1.0 ADMINISTRATIVE 
1.1 Contacts 
A separate contact informat ion list will be provided to each site.
Serious adverse event and pregnancy reporting info rmation is presented in Section 10.0, as is 
inform ation on reporting product complaints. 
Medical and study  drug advice for this protocol is availab le by contacting the Medical Monitor. 
Refer to the study  manual  for contact i nformat ion.
TDC -sponsored invest igators per individual country requirements will be provided with 
emergency medical contact information cards to be carried by  each subject.
General advice on protocol procedures should be obtained through the monitor assigned to the 
study  site. Inf ormation on service providers is given in Sect ion 3.1and relevant guidelines 
provi ded to the si te.
Contact Type/RoleNorth America
ContactEurope
ContactAsia
Contact
Serious adverse event 
and pregnancy reportingSee Section 10.2 See Section 10.2 See Section 10.2
For non-commercial use only
For non-commercial use only
Ixazomib
Study No. C16027 Page 4of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIAL1.3 Protocol Amendment 03 Summary of Changes
Rationale for Amendment 03
This document describes the changes in reference to the protocol incorporating 
Amendment No.03. Patients are eligible to enroll in this rollo ver study  if they  have previ ously 
received and tolerated a defined study  regimen in a desi gnated Takeda -sponsored ixazo mib 
clinical study  (ie, Studi es C16003, C16005, C16006, C16007, C16008, C16010 Global, C16011, 
C16013, C16014 Global and Korean Continuat ion, C16017, C16020, C16029, and C16047) and 
if, in the invest igator’s opinio n, they  may benefi t from  continued therapy  with 1 or m ore of the 
drugs fro m the parent protocol. No new ant icancer agents can be started or added. Note that fo r 
patients whose study  therapy  in a parent study  includes a pl acebo, the pl acebo capsule will be 
discontinued; crossover to ixazo mib is not permitted. The primary reason for this amendment is to 
update the protocol regarding dosing and treatment informat ion from parent protocols.
Addit ionally , this amendment cl arifies other el ements of the study  design and procedures. 
Descript ions of how to manage study  procedures during the coronavirus disease 2019 
(COVID -19) pandemic have been added. Event descript ions we re updated to the current program 
standards for the management of clinical events. Paper -based serious adverse event (SAE) 
reporting procedures were addit ionally  clarified. The list of acceptable methods of contraception 
previously added in the Sweden -specific Protocol Amendment 02 has now been added to this 
global amendment (see Appendix D). See the changes below for a complete list of all changes 
included in this amendment. Minor grammat ical, editorial, and formatting changes are included 
for clarificati on purposes only .
For specific descript ions of text changes and where the changes are l ocated, see Appe ndix E. 
Changes in Amendment 03
1.Updated the legal ent ity of the sponsor.
2.Updated signatories for the study .
3.Clarified that ixazo mib and/ or combinat ional study drugs from the designated parent protocols 
will be provided in this study  until other means of accessing treatment are available; no new 
anticancer agents can be started or added; and for patients whose study  therapy  in a parent 
study includes placebo, the placebo capsule will be discont inued and crossover to ixazo mib is 
not permitted. 
4.Clarified the study  object ives. 
5.Clarified the duration of adverse event (AE) follo w
-up. 
6.Updated the background informat ion on other ixazomib clinica l trials. 
7.Clarified the ant icipated number of patients and sit es/countries.
8.Clarified the duration of an individual pat ient’s study  parti cipat ion. 
9.Clarified the ant icipated total study  durati on.
For non-commercial use only
Ixazomib
Study No. C16027 Page 5of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIAL10.Specified the acceptable methods of contraception to preven t pregnancy . 
11.Clarified that systemic treatment with strong cy tochrome P -450 (CYP)3A inducers is 
prohibited for patients receiving ixazomib during the study .
12.Updated the management of ixazo mib clinical events to align wit h the current program 
standards.
13.Clarified the instructi ons for m anagement of combinat ion therapy  clinical  events. 
14.Updated the storage, handling, and accountabilit y text to clarify procedures and account for the 
COVID -19 pandemic. 
15.Added language regarding alternat ive methods for administe ring study  
procedures/assessments when it is not possible for the patient to come to the study  site due to 
the COVID -19 pandemic.
16.Clarified that pati ents previ ously  enrolled in this study  who rem ain on study  treatment upon 
implementation of Amendment 3 may need to be reconsented, according to IRB/IEC 
standards.
17.Clarified regional except ions for assessment of carbon dioxide, depending on standard of care.
18.Updated the criteria for withdrawing patients fro m study . 
19.Added language to Procedures for Recording an d Reporting Adverse Events and Serious 
Adverse Events.
20.Revised language regarding the statist ical analyses.
21.Clarified l anguage regarding procedures for reporting product complaints or medicat ion 
errors.
22.Clarified l anguage regarding qualit y assurance audits and Regulatory  Agency  inspect ions. 
23.Add informat ion about alternative monitoring approaches, such as remote source data 
verification, in the event a monitor cannot visit the site in a timely manner due to the 
COVID -19 pandemic.
24.Clarify  the ixazomib capsul e strengths that are available.
For non-commercial use only
Ixazomib
Study No. C16027 Page 6of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALINVESTIGATOR AGREEMENT 
I confirm that I have read and that I understand this protocol, the Invest igator’s Brochure, package 
insert and any  other product information provided by  the sponsor. I agree to conduct this study  in 
accordance with the requirements of this protocol and also to protect the rights, safet y, privacy, 
and well -being o f study  subjects in accordance with the following:
The ethical principles that have their origin in the Declaration of Helsinki.
Internationa l Conference on Harmonisation, E6 Good Clinical Pract ice: Conso lidated 
Guideline.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws and 
regul ations.
Regulatory  requi rements for reporting serious adverse events defined in Section 10.0 of this 
protocol .
Terms outlined in the Clinical Study  Site Agreement.
Responsibilit ies o f the Invest igator (Appendix B).
I further authorize that my  personal informat ion may be processed and transferred in accordance 
with the uses contem plated in Appendix Cof this protocol .
Signature of Investigator Date
Invest igator Name (print or ty pe)
Invest igator’s Tit le
Locati on of  Facilit y (Ci ty, State/Provence)
Locati on of  Facilit y (Country )
For non-commercial use only
Ixazomib
Study No. C16027 Page 7of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALTABLE OF CONTENTS
1.0 ADMINISTRATIVE ....................................................................................................... 2
1.1 Contacts ..................................................................................................................... 2
1.2 Approval .................................................................................................................... 3
1.3 Protocol  Amendment 03 Summary  of Changes .......................................................... 4
2.0 STUDY SUMMARY .................................................................................................... 11
3.0 STUDY REFERENCE INFO RMATION ...................................................................... 15
3.1 Study -Related Responsibilit ies................................................................................. 15
3.2 List of Abbreviat ions............................................................................................... 15
4.0 INTRODUCTION ......................................................................................................... 17
4.1 Background ............................................................................................................. 17
4.1.1 Risk: Benefi t Assessment ................................................................................. 18
4.2 Rationale for the Proposed Study ............................................................................. 19
5.0 STUDY OBJECTIVES AND ENDPOINTS .................................................................. 19
5.1 Object ives................................................................................................................ 19
5.1.1 Primary Object ives.......................................................................................... 19
5.2 Endpoints ................................................................................................................. 19
5.2.1 Primary Endpo int............................................................................................. 19
6.0 STUDY DESIGN .......................................................................................................... 19
6.1 Overview of Study  Design ....................................................................................... 19
6.2 Number of Patients .................................................................................................. 21
6.3 Durati on of  Study .................................................................................................... 21
6.3.1 Durati on of  an Individual Pat ient’s Study  Parti cipati on.................................... 21
6.3.2 End of Study /Study  Com pletion Definit ion and Pl anned Reporting .................. 22
6.3.3 Timeframe for Primary  Endpo int to Support Disclosures .................................22
6.3.4 Total  Study  Durati on....................................................................................... 22
7.0 STUDY POPULATION ................................................................................................ 22
7.1 Inclusio n Cri teria..................................................................................................... 22
7.2 Exclusio n Cri teria.................................................................................................... 23
8.0 STUDY DRUG ............................................................................................................. 23
8.1 Study  Drug Adm inistrati on...................................................................................... 23
8.2 Reference/Control Therapy ...................................................................................... 24
8.3 Dose Modificat ion Guidelines .................................................................................. 24
8.4 Excluded Conco mitant Medi cations and Procedures ................................................ 24
8.5 Permi tted Concomitant Medications and Procedures ................................................ 24
For non-commercial use only
Ixazomib
Study No. C16027 Page 8of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIAL8.6 Precauti ons and Restri ctions.................................................................................... 24
8.7 Management of Clinical Events ............................................................................... 25
8.7.1 Management of Ixazo mib Clinical Events ........................................................ 25
8.7.2 Management of Co mbinat ion Therapy Clinical Events .................................... 27
8.8 Blinding and Unblinding .......................................................................................... 27
8.9 Descript ion of Invest igational Agents ...................................................................... 27
8.10 Preparati on, Reconstitution, and Dispensat ion.......................................................... 28
8.11 Packaging and Labeling ................................
........................................................... 28
8.12 Storage, Handling, and Accountabilit y..................................................................... 28
8.13 Combinat ion Therapy .............................................................................................. 29
8.14 Other Protocol -Specified Materials .......................................................................... 29
9.0 STUDY CONDUCT ...................................................................................................... 29
9.1 Study  Personnel and Organizations .......................................................................... 30
9.2 Arrangements for Recruit ment of Patients ................................................................ 30
9.3 Treatment Group Assignments ................................................................................. 30
9.4 Study  Procedures ..................................................................................................... 30
9.4.1 Inform ed Consent ............................................................................................ 31
9.4.2 Vital Signs....................................................................................................... 31
9.4.3 Weight ............................................................................................................. 31
9.4.4 Pregnancy Test ................................................................................................ 31
9.4.5 Concomitant Medications and Procedures ........................................................ 31
9.4.6 Adverse Events ................................................................................................ 32
9.4.7 Enroll ment ....................................................................................................... 32
9.4.8 Clinical Laboratory  Evaluat ions....................................................................... 32
9.4.9 Disease Assessment ......................................................................................... 33
9.5 Com pletion of Study  (for Individual Pat ients).......................................................... 33
9.6 Withdrawal o f Patients From  Study ......................................................................... 33
9.7 Study  Com pliance .................................................................................................... 33
10.0 ADVERSE EVENTS .................................................................................................... 34
10.1 Definit ions............................................................................................................... 34
10.1.1 Adverse E vent Definit ion................................................................................. 34
10.1.2 Serious Adverse Event Definit ion................................
.................................... 34
10.2 Procedures for Recording and Reporting Adverse Events and Serious 
Adverse Events ........................................................................................................ 35
10.3 Moni toring of Adverse Events and Period of Observat ion........................................ 36
10.4 Procedures for Reporting Drug Exposure During Pregnancy and Birth Events ......... 37
For non-commercial use only
Ixazomib
Study No. C16027 Page 9of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIAL10.5 Procedures for Report ing Product Complaints or Medicat ion Errors (Including 
Overdose) ................................................................................................................ 37
10.6 Safety Reporting to Invest igators, IRBs or IECs, and Regula tory Authori ties........... 37
11.0 STUDY -SPECIFIC COMMITTEES ............................................................................. 38
12.0 DAT A HANDLING AND RE CORDKEEPING ............................................................ 38
12.1 eCRFs ...................................................................................................................... 38
12.2 Record Retention ..................................................................................................... 39
13.0 STATISTICAL METHODS .......................................................................................... 39
13.1 Statistical and Analyt ical Plans ................................................................................ 39
13.1.1 Analysis Sets ................................................................................................... 39
13.1.2 Efficacy Analysis ............................................................................................. 39
13.1.3 Safety Analysis ................................................................................................ 40
13.2 Inter im Analysis and Criteria for Early Terminat ion................................................ 40
13.3 Determinat ion of Sample Size .................................................................................. 40
14.0 QUALITY CONTROL AND QUALITY ASSURANCE ............................................... 40
14.1 Study -Site Moni toring Visit s................................................................................... 40
14.2 Protocol  Deviat ions.................................................................................................. 41
14.3 Qualit y Assurance Audits and Regulatory  Agency  Inspect ions................................ 41
15.0 ETHICAL ASPECTS OF T HE STUDY ........................................................................ 42
15.1 IRB and/or IEC Approval ........................................................................................ 42
15.2 Subject Informat ion, Inform ed Consent, and Subject Authorizat ion......................... 43
15.3 Subject Confidentialit y............................................................................................ 44
15.4 Publicat ion, Di sclosure, and Clinical Trial Registration Policy .................................44
15.4.1 Publicat ion....................................................................................................... 44
15.4.2 Clinical Trial Registration ................................
................................................ 45
15.4.3 Clinical Trial Result s Disclosure ...................................................................... 45
15.5 Insurance and Co mpensation for Injury .................................................................... 45
16.0 REFERENCES .............................................................................................................. 46
LIST OF IN -TEXT TABLES
Table 6.a Primary Endpo int for Discl osures ....................................................................... 22
Table 9.a Clinical Chemistry  and Hematol ogy Tests .......................................................... 32
For non-commercial use only
Ixazomib
Study No. C16027 Page 10of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALLIST OF APPENDICES
Appendix A Schedule of Events ............................................................................................. 47
Appendix BResponsibilit ies o f the Invest igator ..................................................................... 49
Appendix C Invest igator Consent to Use of Personal Informat ion.......................................... 51
Appendix D Acceptable Methods of Contraception ................................................................ 52
Appendix E Detailed Descript ion of Amendments to Text ..................................................... 53
For non-commercial use only
Ixazomib
Study No. C16027 Page 11of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIAL2.0 STUDY SUMMARY 
Name of Sponsor(s):
Takeda Development Center Americas, IncCompound:
Ixazomib
Title of Protocol: An Open -Label, Rollover Protocol for 
Patients Previously Enrolled in Takeda -Sponsored 
Ixazomib Studies EudraCT No.:
2016 -001681 -28
Study Number: C16027 Phase: 2
Study Design:
This is an open -label, multicenter, rollover study to provide continued access to ixazomib and/or other combinational 
study drugs from the designated ixazomib parent protocols when the patient has no other means to access study 
treatment. The study will al so evaluate the long -term safety profile of ixazomib. 
The patient population will consist of patients who have previously received and tolerated a defined study regimen in 
a designated Takeda -sponsored ixazomib clinical study, and in the investigator’s opinion and approved by the Takeda 
medical monitor, may benefit from continued therapy with 1 or more of the study drugs from a parent protocol (eg, 
response to therapy or stable disease without evidence of disease progression). 
Patients may be enrolled provided they have not met any of the discontinuation criteria in a parent study. Patients will 
enter this study on the same dose, schedule of study drug(s), and combination regimen that they were receiving at the 
time of rollover from the parent study, or according to the required dose modification from a parent study. For those 
patients who received ixazomib dosing based on body surface area (BSA) per the parent study, the dose may be 
rounded. The dose may also be rounded for thos e patients who convert from BSA -based dosing to fixed dosing with 
approval from the Medical Monitor. No new anticancer agents can be started or added. Note that for patients whose 
study therapy in a parent study includes a placebo, the placebo capsule will be discontinued; crossover to ixazomib is 
not permitted. 
Following enrollment, patients may receive study treatment until they experience disease progression, clinical 
deterioration in the investigator’s judgment, experience an unacceptable toxicity, wit hdraw consent, pursue an 
alternative therapy, meet other study -specified reasons for discontinuation of study drug, or until the patient is 
transitio ned to ixazomib/other therapy through commercial channels. 
Patients participating in a designated parent s tudy will enter the rollover study when they have completed the end of 
treatment (EOT) visit in the parent study and when the rollover study is active at the investigative site. Following their 
provision of informed consent to continue receiving treatment in the rollover study, patients will be provided with 
study medication. Patients should enter the study within a maximum of 8 weeks of their last dose of study drug(s) in 
the parent study or as agreed upon by the Takeda clinician/designee so to minimize an y treatment disruption to the 
patient. Local safety -related laboratory evaluations and vital sign measurements will be performed according to the 
schedule of events as presented in this rollover study and accordingly will only be recorded in the electronic case 
report forms (eCRFs) prior to the first dose of ixazomib in the rollover study, at the end of study, and as spontaneously 
reported by the investigator. Electrocardiogram assessments will only be performed as clinically indicated. During 
treatment, do sing modification decisions will be made per the parent study. Systemic treatment with strong 
cytochrome P -450 (CYP)3A inducers is prohibited for patients receiving ixazomib during the study. The procedures 
prohibited in the patient’s parent study are prohibited during this study. Prohibited medications due to 
co-administration of other agents in the ixazomib regimen are prohibited as per the prescribing information for the 
co-administered agent(s).
It is recommended that disease assessments are performed p er standard of care. 
At the time of discontinuation of study drug(s) in this study, an end -of-study  (EOS) visit will be scheduled and will 
occur prior to the initiation of any new therapy, or within 30 days of last dose of study drug administration, which ever 
is earlier. The reason for treatment discontinuation, an overall investigator assessment of best response obtained 
during this rollover study, and the investigator assessment of date of progression will be captured in the eCRFs. 
Toxicity will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events, 
For non-commercial use only
Ixazomib
Study No. C16027 Page 12of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALVersion 5.0, effective date 27 November 2017 [1]. 
The lo ng-term safety and tolerability of ixazomib will b e monitored. The following adverse events (AEs) will be 
reported from the first dose of study drug for this study through 30 days after administration of the last dose of study 
drug and recorded in the eCRFs and serious adverse events ( SAEs) will also be r eported directly to the Sponsor (see 
Section 10.2). The following AEs that are ongoing at the time of entry into the rollover study will be recorde d in the 
eCRFs as baseline AEs .
All SAEs.
All ≥Grade 3 AEs.
≥Grade 2 peripheral neuropathy.
New primary malignancies.
Any AE resulting in dose modification or discontinuation of any study drug.
Any other AE that in the opinion of the investigator is a clinically significant event.
The above AEs will be followed until resolution, until the AE becomes chronic or stable, or is determined to be part of 
the underlying disease process, or until the patient attends the EOS visit and discontinues the study.
Thetransfer of patients between sites is allowed with the approval of the sponsor’s clinician/designee (eg, in the case 
of site closure, patient moves, etc).
Primary Objective:
To provide continued access to ixazomib and/or other study drugs from an ixazomi b parent study. 
To evaluate the long -term safety profile of ixazomib. 
Subject Population: Patients on study drug(s) at the closure of an ixazomib parent study, and who are likely to derive 
benefit from continued study therapy.
Number of Subjects:
The estimated number of patients to be enrolled is 
approximately 250. Number of Sites: 
The number of countries and sites is not currently 
specified as this study is open to all countries and sites 
with qualifying patients from prior 
company -sponsored ixa zomib studies
Dose Level(s):
Patients will enter this study on the same same dose, 
schedule of study drug(s), and combination regimen that 
they were receiving at the time of rollover from the parent 
study, or according to the required dose modification from a 
parent study. No new anticancer agents can be started or 
added. Note tha t for patients w hose study  therapy in a 
parent study includes a placebo, the placebo capsule will be 
discontinued; crossover to ixazomib is not permitted. 
For those patients who received ixazomib dosing based on 
body surface area (BSA) per the parent stud y, the dose may 
be rounded. The dose may also be rounded for those 
patients who convert from BSA -based dosing to fixed 
dosing with approval from the Medical Monitor. Route of Administration:
Oral
For non-commercial use only
Ixazomib
Study No. C16027 Page 13of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALDuration of Treatment:
The anticipated duration of treatme nt in this rollover study 
will be approximately 5 years. Patients may remain in the 
rollover study until they are transitioned to ixazomib/other 
therapy  through commercial channels or until any of the 
other reasons for treatment discontinuation are met, 
whichever is sooner.Period of Evaluation:
Patients will be followed for 30 days after the last dose 
of ixazomib/other study drug(s) or the start of 
subsequent alternative anticancer therapy.
Duration of Study:
The estimated time frame for study completion (first patient 
in to last patient last visit) is approximately 7 years.
Main Criteria for Inclusion:
Patients previously treated with ixazomib, background therapy, and/or comparator drugs (including placebo) in a 
Takeda -sponsored ixazomib parent study. Patients will be eligible to enter the rollover study when:
a)The parent study is closed or planned to be closed; and
b)The patient is on ixazomib monotherapy, a combination regimen with ixazomib and other study medication(s), 
on a placebo combination, or on a n alternative arm regimen in a designated ixazomib parent study (ie, Studies 
C16003, C16005, C16006, C16007, C16008, C16010 Global, C16011, C16013, C16014 Global and Korean 
Continuation, C16017, C16020, C16029, and C16047); and
c)In the opinion of the invest igato rand approved by the Takeda medical monitor, the patient may continue to 
benefit from treatment with ixazomib and/or another study drug/combination regimen (eg, response to therapy or 
stable disease without evidence of disease progression) and has no alternate means to access the study drug(s) 
(eg, commercial supply). 
Main Criteria for Exclusion:
Patients meeting any of the criteria for treatment discontinuation in the parent study.
Main Criteria for Evaluation and Analyses:
The primary endpoint is safety, as assessed by the incidence of the following AEs:
All SAEs.
All ≥Grade 3 AEs.
≥Grade 2 peripheral neuropathy.
New primary malignancies.
Any AE resulting in dose modification or discontinuation of any study drug.
Any other AE that in the opinion o f the investigator is a clinically significant event.
Statistical Considerations:
The following AEs will be summarized for patients who receive at least 1 dose of ixazomib using the full analysis set: 
All SAEs.
All ≥Grade 3 AEs. 
≥Grade 2 peripheral neur opathy.
New primary malignancies. 
Any AE resulting in dose modification or discontinuation of any study drug.
Any other AE that in the opinion of the investigator is a clinically significant event. 
No formal statistical testing or inferential statistics will be generated.
All AEs will be coded using the Medical Dictionary for Regulatory Activities. Data will be summarized using 
preferred term and primary system organ class. Local laborator y assessment changes and vital sign changes from 
study entry to end of study will also be summarized.
Exposure to study drug and study regimen will be tabulated. In addition, reasons for drug discontinuation will be 
For non-commercial use only
Ixazomib
Study No. C16027 Page 14of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALsummarized. 
The overall investigator assessment of best response obtained during this rollover study and i nvestigator assessment of 
date of progression will be listed.
Concomitant medications and procedures related to treatment of AEs from screening through the study period will be 
classified by generic terms according to the World Health Organization drug dic tionary. 
Data will be presented by the entire ixazomib Safety population, by population of monotherapy of ixazomib, and by 
populatio n of ixazomib in combination with other anticancer agents(s), as specified in the SAP. Safety listings will be 
prepared for patients receiving other study drugs and not ixazomib. Additional safety analyses by subgroups such as 
drug indication and baseline characteristics may be performed, as specified in the SAP. 
Sample Size Justification: There is no statistical hypothesis and no power considerations in this study.
For non-commercial use only
Ixazomib
Study No. C16027 Page 15of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIAL3.0 STUDY REFERENCE INFO RMATION
3.1 Study -Related Responsibilities 
The sponsor will perform all study -related activit ies wi th the except ion of those i dentified in the 
vendor con tact informat ion. The i dentified vendors in the template for specific study -related 
activit ies will perform these act ivities in full or in partnership wi th the sponsor.
3.2 List of Abbreviations
AE adverse event
AL amy loidosis systemic light -chain amyloidosis
ASCT autologous stem cell transplant
ALP alkaline phosphatase
ALT alanine aminotransferase
ANC absolute neutrophil count
aPTT activated partial thromboplastin time
AST aspartate aminotransferase
BUN blood urea nitrogen
BSA body surface area
CO 2 carbon dioxide
eCRF case report form (electronic or paper)
CRO contract research organization
CYP cytochrome P -450
ECG electrocardiogram
EOS end of study
EOT end of treatment
FAS full analy sis set
FDA Food and Drug Administration
GCP Good Clinical Practice
GGT -glutamy l transferase
ICH International Conference on Harmonisation
IEC independent ethics committee
IRB institutional review board
IV intravenous
IVRS interactive voice response system
IWRS interactive web response system
LDH lactate dehydrogenase
LenDex lenalidomide plus dexamethasone
MedDRA Medical Dictionary for Regulatory Activities
MLN2238 research name for ixazomib, the biologically active boronic acid form of the drug 
substance
For non-commercial use only
Ixazomib
Study No. C16027 Page 16of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALMLN9708 research name for ixazomib citrate, the stable citrate ester of ixazomib
MM multiple myeloma
NCI CTCAE Natio nal Cancer Institute Common Terminology Criteria for Adverse Events
NDMM newly  diagnosed multiple myeloma 
RRAL amyloidosis relapsed and/or refractory systemic light -chainamyloidosis 
RRMM relapsed and/or refractory multiple myeloma
SAE serious adverse event
SAP statistical analysis plan
SmPC Summary of Product Characteristics
SUSAR suspected unexpected serious adverse reaction
US United States
USPI United States Prescribing Information
For non-commercial use only
Ixazomib
Study No. C16027 Page 17of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIAL4.0 INTRODUCTION
4.1 Background
Ixazo mib is an invest igational, oral , inhibi tor of  the 20S proteasome that has been studied for the 
treatm ent of m ultiple myelo ma (MM), pl asma cell  dyscrasias, amylo idosis, lympho ma, 
nonhematologic malignanc ies, and lupus nephrit is. Inhibit ion of the 20S proteasome has been 
validated as a therapeuti c target for the treatm ent of malignancies using VELCADE®(bortezomib) 
for Injecti on, Takeda ’s first-in-class proteasom e inhibitor [2]. 
Oral ixazomib in co mbinat ion with lenalido mide and dexamethasone was first approved by the 
United States (US) Food and Drug Administration (FDA) in November 2015 for the treatment of 
patients wi th MM who have received at least 1 prior therapy  [
3,4].It has since been approved in 
over 65 countries globally.
Ixazo mib (MLN2238) refers to the bio logically active boronic acid form of the drug substance. 
The drug substance is administered as a stable citrate ester, designated as ixazo mib citrate 
(MLN9708). Under physio logical condi tions, ixazomib citrate rapidly hydrolyzes to the 
biologically  active boroni c acid, i xazo mib. Ixazo mib is a pept ide boronic acid that is structurally 
different fro m bortezomib.
Detailed informat ion rega rding the nonclinical pharmaco logy and toxicology of MLN9708 may be 
found in the ixazo mib IB.
Phase 1, phase 1/2, and phase 2 trials have been conducted in MM, relapsed and/or refractory  
systemic light -chain amylo idosis (RRAL), solid tumors, and lympho ma. In addit ion, phase 1 
studi es were conducted in patients with renal impairment who had relapsed and/or refractory  
multiple myelo ma (RRMM) or advanced so lid tumors (Study C16015), in pat ients with hepati c 
impairment who had advanced so lid tumors or hematolog ic malignancies (Study  C16018), and in 
an absorption, distribut ion, metabo lism, and excretio n study  in pat ients with advanced so lid 
tumors or lympho ma (Study  C16016). Phase 3 trials in RRMM (C16010), newly diagnosed 
multiple myelo ma (NDMM) (C16014), and RR AL (C16011) have addit ionally been co mpleted. 
Phase 3 trials o f ixazo mib as maintenance therapy fo llowing autol ogous stem  cell transplantati on 
(C16019) or in pat ients who did not receive ASCT (C16021) are ongoing.
Ixazo mib had been available as an IV and oral formulat ion (during the early development of 
ixazo mib); however, only the oral formulat ion is currently being developed for commercializat ion. 
Regardless of the route of administration, in the twice -weekly dosi ng schedule, ixazomib is given 
on Days 1, 4, 8, and 11 of a 21 -day cycle, and in the weekly dosing schedule, ixazo mib is given on 
Days 1, 8, and 15 of a 28 -day cycle. Schedules with longer cy cles are being invest igated in Study 
C16006. 
The fo llowing oncol ogy indicat ions have been studied during the clinical development of 
ixazo mib: RRMM, NDMM, RRAL, advanced so lid tumors, advanced lympho ma, and pediatric 
acute lymphoblast ic leukemia. Studies are invest igating both single -agent i xazo mib and ixazo mib 
in comb
ination with standard treatm ents. 
For non-commercial use only
Ixazomib
Study No. C16027 Page 18of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALFurther details on these studies are provided in the ixazo mib IB.
4.1.1 Risk: Benefit Assessment
4.1.1.1 Risks
The ri sks (i dentified and potential) have been assessed in clinical and nonclinical studies and are 
detailed in the current versio n of the IB. The emerging safet y profile indicates that oral ixazo mib is 
generally well tolerated and, while some potential toxicit ies may be severe, the predominant 
toxicities are l argely reversible, able to be monitored by  routine clinical  examinat ion, and 
manageable by dose reductions, discontinuation, or standard supportive care. It is possible that 
ixazo mib will have toxicit ies that were not predicted fro m its evaluation in nonclinical studies or 
previously observed in ongo ing clinical studies. T o mit igate the inherent risks in clinical studies o f 
ixazo mib, patients are monitored closely for anticipated toxicit ies. Guidance for the management 
of adverse events (AEs) and procedures for reducing doses are provided (see Sect ion 8.3and 
Secti on 8.7), and drug dosage can be reduced either by  decreasing the dose administered or by  
interrupti on of  the scheduled treatment. Further information is provided in th e IB.
Risks associated with ixa zomib therapy have been ident ified fro m ongoing clinical studies as well 
as the registrational trial o f ixazo mib plus lenalidomide and dexamethasone in the treatment of 
patients wi th MM who have received at least 1 prior therapy  (see the current IB and the United 
States Prescribing Informat ion (USPI) for further informat ion). These include blood and 
lymphat ic system disorders (thrombocytopenia, neutropenia and anemia [all reversible]), 
gastrointestinal toxicit ies (diarrhea, nausea, vo miting, and const ipation), general disorders 
(fatigue, peripheral edema, and pyrexia), metabo lism and nutri tion di sorders (decreased appetite), 
nervous system disorders (dizziness, dy sgeusia, peri pheral  neuropathy  [generally  Grades 1 or 2]), 
psychiatric disorders (insomnia), ski n and subcutaneous tissue disorders (rash [very  comm on], 
severe dermal events [rare]).
Refer to the current IB for the list of potential risks of ixazo mib.
4.1.1.2 Benefits
Ixazo mib in co mbinat ion with lenalido mide and dexamethasone was approved by the US FDA in 
November 2015 for the treatment of patients with MM who have received at least 1 prior therapy 
[3,4] . The exploration of other therapeutic areas is ongoing. To date, activit y in MM has been see n 
with single -agent ixazo miband wi th ixazo mib combined with established therapies. In addit ion, 
single
-agent activit y has been observed in relapsed amylo idosis and indo lent non-Hodgkin 
lympho ma. This study will provide continued access to ixazo mib and/or other combinat ional study 
drugs from the designated ixazomib parent protocols when the patient has no other means to access 
study  treatm ent. Qualified patients who have been deriving benefit in an ixazo mib parent protocol 
will receive treatment in this study  until they are transit ioned to ixazomib/other therapy  through 
commercial channels or until any of the other reasons for treatment discontinuat ion are m et, 
whichever i s sooner. Based on approval by the Takeda medical monitor every  24 m onths, 
continued access to ixazo mib and/or othe r study  drugs will  be allowed f or pati ents who in the 
investigator’s opinion are deriving clinical benefit.
For non-commercial use only
Ixazomib
Study No. C16027 Page 19of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIAL4.2 Rationale for the Proposed Study
The primary  purpose of thi s rollo ver study  is to cont inue to provide ixazo mib and/or other 
combinat ional study  drug s to patients who have previously received and tolerated treatment in an 
ixazo mib parent study, and in the invest igator’s opinio n may benefit from cont inued therapy wit h 
1 or m ore of the drugs from the parent protocol (eg, patient demonstrates response to therapy  or 
stable disease wit hout evidence of disease progressio n). The study will also evaluate the long -term 
safet y profile of ixazo mib in those pati ents who cont inue to receive ixazo mib. 
5.0 STUDY OBJECTIVES AND ENDPOINTS
5.1 Objectives
5.1.1 Primary Objectives
The primary  object ives are:
To provi de continued access to ixazo mib and/or other study drugs fro m an ixazo mib parent 
study .
To evaluate the long -term safet y profile o f ixazo mib.
5.2 Endpoints
5.2.1 Primary Endpoint
The primary  endpoint is safet y of ixazomib, as assessed by the incidence o f the following AEs:
All serious adverse events (SAEs).
All ≥Grade 3 AEs.
≥Grade 2 peripheral neuropathy .
New primary malignancies.
Any AE result ing in dose modificat ion or di scont inuat ion of any  study  drug.
Any other AE that in the opin ion of the invest igator is a clinically significant event.
6.0 STUDY DESIGN
6.1 Overview of Study Design
This is an open -label, mult icenter, rollo ver study  to provi de cont inued access to ixazo mib and/or 
other study  drugs fro m a designated ixazo mib parent study (ie, Studi es C16003, C16005, C16006, 
C16007, C16008, C16010 Global, C16011, C16013, C16014 Global and Korean Cont inuat ion, 
C16017, C16020, C16029, and C16047) when the patient has no other means to access study 
treatm ent. The study  will also evaluate the l ong-term safet y profile o f ixazo mib in those patients 
who continue to receive ixazo mib. The pat ient populat ion will consist of patients who have 
For non-commercial use only
Ixazomib
Study No. C16027 Page 20of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALpreviously received and tolerated treatment in a Takeda -sponsored clinical study of ixazo mib, and 
in the invest igator’s opi nion and approved by the Takeda medical mo nitor, m ay benefi t from 
continued therapy  with 1 or m ore of the drugs from a parent protocol (eg, patient demonstrates 
response to therapy  or stabl e disease wi thout evi dence o f disease progressi on). 
Patients may be enrolled provi ded they  have not met any  of the di scont inuat ion criteria in their 
parent study . Pati ents will enter this study  on the sam e ixazomib dose, schedule of study  drug(s), 
and co mbinat ion regimen that they were receiving at the time of r ollover fro m the parent study, or 
according to the required dose modificat ion from a parent study  (Secti on 8.1). For those patients 
who received ixa zomib dosing based on BSA per the parent study, the dose may be rounded. The 
dose m ay also be rounded for those patients who convert from BSA -based dosing to fixed dosing 
with approval  from the Medical Monitor. No new ant icancer agents can be started or added. Note 
that for patients whose study therapy in a parent study includes a placebo, the placebo capsule will 
be discont inued; crossover to ixazo mib is not permitted.
Following enro llment, patients may receive study drug(s) until they experience disease 
progression, clinical deterioration in the invest igator’s judgment, experience an unacceptable 
toxicity, withdraw consent, pursue an alternat ive therapy, meet other study -specified reasons for 
discontinuat ion of study drug, or until the patient is transit ioned to ixazo mib/other therapy through 
commercial channels . 
Patients parti cipating in a designated ixazomib parent study  will enter the rollo ver study  at the 
time
-point when they  have co mpleted the EOT visit in the parent study  and when the rollo ver 
study  is act ive at an invest igative site. Fo llowing their provi sion of informed consent to receive 
treatm ent in the rollo ver study , pati ents will be provided with study  medicat ion. Pati ents shoul d 
enter the study wit hin 8 weeks o f their last dose of ixazo mib/oth er study drug(s) in the parent study 
or as agreed upon by the Takeda clinician/designee so to minimize any treatment disruption to the 
patient. Local safet y-related laboratory evaluat ions and vital sign measurements will be performed 
according to the sched ule of  events as presented in this study  and accordingly  will only be 
recorded in the electronic case report forms (eCRF) prior to the first dose of study  drug in the 
rollover study , at the end of study , and as spontaneously reported by  the invest igator. 
Electrocardiogram (ECG) assessments will only be performed as clinically indicated. During 
treatm ent, dosing modificat ion decisio ns will be made per the parent study. For pati ents receiving 
ixazo mib, systemic treatment with strong cy tochrome P -450 (CYP)3A i nducers (rifabutin, 
carbamazepine, phenyto in, phenobarbital), or use of St. John’s wort) is prohibited during the 
study . The procedures prohibited in the patient’s parent study  are prohibited during this study . 
Prohibited medicat ions due to co -administrati on of other agents in the ixazo mib regimen are 
prohibited as per the prescribing information for the co -administered agent(s).
It is recommended that disease assessments are performed per standard of care. 
At the time of discont inuat ion of study  drug(s) i n this study , an end -of-study  (EOS) vi sit will be 
scheduled and will occur prior to the init iation of any new therapy, or within 30 days of last dose of 
study  drug administrati on, whichever is earlier. The reason for treatment discont inuat ion, an 
overall i nvest igator assessment of best response obtained during this rollo ver study , and the 
investigator assessment of date of progression will be captured in the eCRFs.
For non-commercial use only
Ixazomib
Study No. C16027 Page 21of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALToxicit y will be evaluated according to National Cancer Inst itute Commo n Termino logy Criteria
for Adverse Events (NCI CTCAE), Version 5.0, effect ive date 27 November 2017 [1]. 
The l ong-term safet y and tol erabili ty of ixazo mib/other study  drug(s) will b e monitored. The 
following AEs will be reported from the first dose of study drug in this study through 30 days after 
administration of the last dose of study  drug and recorded i n the eCRFs and SAEs will also be 
reported direct ly to the Sponsor (see Sectio n
 10.2). The fo llowing AEs that are ongoing at the time 
of entry  into the rollo ver study  will be recorded in the eCRFs as baseline AEs .
All SAEs.
All ≥Grade 3 AEs. 
≥Grade 2 peripheral neuropathy .
New primary malignancies. 
Any AE result ing in dose modificat ion or discont inuat ion of any  study  drug.
Any other AE that in the opinio n of the invest igator is a clinically significant event.
The above AEs w ill be followed unt il reso lution, unt il the AE beco mes chronic or stable, or is 
determined to be part of the underlying disease process , or until the patient attends the EOS visit 
and discont inues the study.
The transfer of patients between sites is allow ed wi th the approval  of the sponsor’s 
clinician/designee (eg, in the case of site closure, patient moving, etc).
6.2 Number of Patients
The est imated number of pat ients to be enrolled is approximately 250 .The number of countries 
and sites is not currently  specified as this study  is open to all countries and sites with qualifying 
patients f rom prior com pany -sponsored ixazo mib studies.
Enrollment is defined as when the patient receives the first dose of study  drug in thi s rollo ver 
study .
6.3 Duration of Study
6.3.1 Duration of an Individual Patient’s Study Participation
The ant icipated durati on of  treatm ent for an individual  patient in this rollo ver study  will be 
approximately  5 years. Based on approval by  the Takeda m edical m onitor every  24 m onths, 
continued access to ixazo mib and/or other study drugs will be allowed for patients who in the 
investigator’s opinio n are deriving clinical benefit. Patients may remain in the rollo ver study  until 
they are transi tioned to ixazo mib/other therapy  through commercial channels o r until any  of the 
other reasons for treatment discont inuat ion are m et, whi chever i s sooner.
Patients will  be followed for 30 days after the last dose of study  drug(s). 
For non-commercial use only
Ixazomib
Study No. C16027 Page 22of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALOngo ing AEs meet ing the criteria in Sect ion 10.2 will be fo llowed unt il resolut ion, unt il the AE 
beco mes chronic or stable or is determined to be part of the underlying disease process, or until the 
patient attends the EOS visit and d iscont inues the study. 
6.3.2 End of Study/Study Completion Definition and Planned Reporting
Primary Co mpletion/Study  Com pletion
The est imated time frame for study complet ion (first pati ent in to l ast pati ent last visit) i s 
approximately  7years.
The final analyses for the primary endpoint and single final clinical study report will be conducted 
following the end of the study .
6.3.3 Timeframe for Primary Endpoint to Support Disclosures
Please refer to Table 6.afor disclosures information for the primary endpo int.
Table 6.a Primary Endpoint for Disclosures
Endpoint Maximum Time Frame
Primary : 
The incidence of the following AEs:
All SAEs.
All ≥Grade 3 AEs. 
≥Grade 2 peripheral neuropathy.
New primary malignancies. 
Any AE resulting in dose modification or 
discontinuation of any study drug.
Any other AE that in the opinion of the investigator is a 
clinically s ignificant event.Approximately 5 years of treatment with study drug(s) 
for an individual patient in this study. Overall, 
assessment of the primary endpoint will be 
approximately 7 years after the first patient is enrolled 
in the study. 
AE=adverse event ; SAE=serious adverse event.
6.3.4 Total Study Duration
It is ant icipated that this study  will last for approximately 7 y ears. 
7.0 STUDY POPULATION
7.1 Inclusion Criteria
Each patient must meet all of the fo llowing inclusion criteria to be enrolled in the study :
1.Voluntary  written consent must be given before performance of any study -related procedure 
not part of standard medical care. Patients should consent and enter the study  within a 
maximum o f 8 weeks of their last dose of treatment in the parent study  or as a greed by  the 
Takeda clinic ian/designee.
For non-commercial use only
Ixazomib
Study No. C16027 Page 23of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIAL2.Previously  treated wi th ixazo mib, background therapy ,and/or com parator drugs (including 
placebo) in a Takeda -sponsored ixazo mib parent study. Patients will be eligible to enter the 
rollover study  when:
a)The parent st udy is closed or planned to be closed; and
b)The patient is on ixazo mib monotherapy , a combinati on regimen wit h ixazo mib and other 
study  medicat ion(s), on a placebo combinat ion, or on an alternat ive arm regimen in a 
designated ixazomib parent study  (ie, Stud ies C16003, C16005, C16006, C16007, 
C16008, C16010 Global, C16011, C16013, C16014 Global and Korean Continuation, 
C16017, C16020, C16029, and C16047); and
c)In the opinio n of the invest igator and approved by the Takeda medical mo nitor, the patient 
may cont inue to benefit fro m treatm ent wi th ixazomib and/or another study  
drug/combination regimen (eg, response to therapy or stable disease without evidence o f 
disease progressi on) and has no al ternate m eans to access the study  drug(s) 
(eg,commercial supply).
3.Agree to continue to practice contraceptive methods as outlined in the parent study. See 
Appendix Dfor acceptable methods of contraception. 
7.2 Exclusion Criteria
Patients m eeting any o f the following exclusio n criteri a are not to be enrolled in the study :
1.The patient meets any of the criteria for treatment discontinuat ion in the parent study .
2.Female pat ients who are lactating and breastfeeding or have a positive serum  pregnancy  test 
during the eligibilit y period.
8.0 STUDY DRUG
8.1 Study Drug Administration
All study -specific criteria for administration of study  drug m ust be m et and docum ented pri or to 
drug administration. Study  drug will be administered only  to eligible pat ients under the 
supervisio n of the invest igator or ident ified subinvestigator(s).
Ixazo mib, as a single agent or in co mbinat ion with other study  drugs, will be administered 
according to the dose, schedule, and co mbination regimen the patient wa s receiving at the time o f 
rollover fro m the parent study , or according to the required dose modificat ion from a parent study . 
For those patients who received ixazo mib based on BSA dosing per the parent study, the dose may 
be rounded. The dose may also be rounded for those patients who convert from BSA -based dosing 
to fixed dosing with approval fro m the Medi cal Moni tor. No new anticancer agents can be started 
or added. Note that for patients whose study  therapy  in a parent study  includes a placebo, the 
placebo capsule will be discont inued; crossover to ixazo mib is not permitted. 
Patients will  be given ixazomib as a single, oral dose on a 21 -or 28 -day cycle according to the 
parent protocol. Patients should be instructed to swallow ixazo mib capsules who le wi th water and 
For non-commercial use only
Ixazomib
Study No. C16027 Page 24of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALto not break, chew, or open the capsules. Ixazo mib should be taken on an empt y stom ach at l east 
1hour before or no sooner than 2 hours after a meal. Each capsule should be swallowed separately 
with a sip of water. A total  of approximately  8 oz (240 mL) of water should be taken with the 
capsules. 
Missed doses can be taken as soon as the patient remembers if the next scheduled dose is 72 hours 
or more away . A doubl e dose shoul d not be taken to make up for a missed dose. If the patient 
vomits after taking a dose, the patient should not repeat the dose but should resume dosing at the 
time of the next scheduled dose.
8.2 Reference/Control Therapy 
Patients whose study  treatm ent in a parent study  includes a pl acebo will  discontinue the pl acebo 
capsule w hen they  enter thi s study . Other study  medication(s)/alternative arm therapies 
administered during the parent protocol will be cont inued according to the dose, schedule, and 
regimen the patient was receiving at the time of rollo ver from the parent study , or according to the 
requi red dose m odificat ion from a parent study .
8.3 Dose Modification Guidelines
Toxicit y will be evaluated according to NCI CTCAE, Versi on5.0, effect ive date 27 November 
2017 [1]. 
Dose m odificat ions for the m anagement of AEs will be made according to the parent study . 
8.4 Excluded Concomitant Medications and Procedures
The fo llowing m edicat ions are prohibited during this study : 
For pati ents receiving ixazomib, systemic treatment with strong CYP3A inducers (rifampin, 
rifapentine, rifabut in, carbamazepine, phenytoin, phenobarbital), or use of St. John’s wort.
The procedures prohibited in the patient’s parent study are prohibited during this study. Prohibited 
medicat ions due to co -admini strati on of  other agents are prohibited as per the prescribing 
inform ation for the co -administered agent(s).
8.5 Permitted Concomitant Medications and Procedures 
All necessary  supportive care consistent with optimal patient care shall be available to patients as 
needed.
8.6 Precautions and Restrictions
It is not known what effects ixazo mib has on human pregnancy or development of the embryo or 
fetus. Pregnancy prevent ion measures as per the patient’s parent study should cont inue to be used.
Therefore, female patie nts participat ing in this study should avoid beco ming pregnant, and male 
patients should avo id impregnat ing a female partner. Nonsterilized female pat ients of reproductive 
age and male patients should use effect ive methods of contraception through defined periods 
during and after study  treatm ent as specified in the parent study .
For non-commercial use only
Ixazomib
Study No. C16027 Page 25of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIAL8.7 Management of Clinical Events 
8.7.1 Management of Ixazomib Clinical Events
Prophylaxis Against Risk of Reactivation of Herpes Infection
Patients may be at an increased risk of infection, including react ivation of herpes zoster and herpes 
simplex viruses. All pat ients continuing to receive ixazo mib in this rollo ver study  shoul d receive 
prophylact ic antiviral therapy. Patients receiving a non -ixazo mib-containing regimen should be 
guided by  the physician's clinical pract ice.
Nausea or Vomiting
Prophylaxis wit h standard ant iemetics, including serotonin 5 -hydroxy tryptamine 3 receptor 
antagonists, is reco mmended for emesis. Any fluid deficit occurring during treatment should be 
prom ptly corrected. 
Diarrhea
Diarrhea shoul d be managed according to c linical practice, including the administration of 
antidiarrheals once infect ious causes are excluded. Fluid intake should be maintained to avoid 
dehydrat ion. Any fluid deficit occurring during treatment should be promptly corrected.
Erythematous Rash With or Without Pruritus
Rash may  range from  limited ery thematous areas, macular or small papular bumps that may or 
may not be prurit ic over a few areas o f the body , to a m ore generalized eruption that is 
predominant ly on the trunk or extremit ies. Rash has been most commonly characteri zed as 
maculopapular or macular. To date, when it does occur, rash is most commo nly reported within the 
first 3 cycles of therapy. The rash is often transient and self -limit ing and is typically Grade 1 or 2 in 
severit y. If rash occ urs, considerat ion should be given to alternate causes of the rash such as 
concomitant medicat ions, infect ions, etc ; these other causative agents should be discont inued and 
alterative agents considered if medically  necessary .
Symptom atic m easures such as a ntihistamines or corticosteroids (oral or topical) have been 
successfully used to manage rash and have been used prophylactically  in subsequent cy cles. The 
use of a topical, IV, or oral steroid (eg, prednisone ≤ 10 mg per day  or equivalent) is permitted. 
Management of a Grade 3 rash may require IV antihistamines or corticosteroids. Administration of 
ixazo mib (and other causative agent if given in co mbinat ion) should be modified and re -initiated at 
a reduced level fro m where rash was noted (per parent study ). In line wit h clinical pract ice, 
derm atology consul t and bi opsy of Grade 3 or hi gher rash or any  SAE involving rash is 
recommended. Prophylact ic measures should also be considered if a patient has previously 
developed a rash (eg, using a thick, alcoho l-free emollient cream on dry areas of the body or oral or 
topical ant ihistamines). 
The rare risks of Stevens -Johnson syndro me, toxic epidermal necrolysis (TEN), drug reaction wit h 
eosinophilia and systemic symptoms (DRESS syndrome), and pemphigus vulgaris h ave been 
reported in onco logy studies when ixazo mib (or placebo) was given wit h conco mitant medications 
For non-commercial use only
Ixazomib
Study No. C16027 Page 26of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALthat are known to cause rash (eg, Bactrim, lenalidomide, aspirin), and/or in the setting of 
confounding treatment -emergent AEs. These severe, potentiall y life-threatening or deadly  
condi tions may  involve rash with skin peeling and mouth sores and should be clinically managed 
according to standard medical practice. Punch biopsies for histopathological analysis are 
encouraged at the discretion of the invest igator. Study medicat ions should be discontinued in the 
event of severe, potentially life -threatening rash. Addit ional information regarding these react ions 
can be found in the IB.
Thrombocytopenia
Blood counts shoul d be m onitored regul arly according to st andard clinical pract ice. 
Thrombocy topeni a may be severe but has been manageable with platelet transfusio ns according to 
standard clinical pract ice. Ixazo mib administration should be modified according to dose 
modificati on recommendat ions in the parent stu dy when thrombocytopenia occurs. Therapy can 
be reinit iated at a reduced level upon recovery  of platel et counts. Thrombotic microangiopathy  
(TMA), including thrombotic thrombocy topeni a purpura and hemo lytic uremic syndrome, are 
rare, serious blood disorder s that cause low levels of platelets and red blood cells and result in 
blood clots in small blood vessels. Symptoms may include fat igue, fever, bruising, nose bleeds, 
and decreased urinat ion. These disorders, including fatal cases, have been reported in pa tients 
receiving ixazo mib. If TMA is suspected, consider withdrawal o f the suspected causative agent 
and manage according to standard medical pract ice.
Neutropenia
Blood counts shoul d be m onitored regul arly with addi tional testing, as appropri ate, according to 
standard clinical pract ice. Neutropenia may be severe but has been manageable. Growth factor 
support is not required but may be considered according to standar d clinical pract ice. Ixazo mib 
administration should be modified according to dose modificat ion recommendat ions in the parent 
study  when neutropenia occurs. Therapy  can be reinit iated at a reduced level upon recovery  of 
absolute neutrophil count (ANC). 
Fluid Deficit
Dehydrat ion should be avo ided because ixazo mib may cause vo miting, diarrhea, and dehydrat ion. 
Acute renal failure has been reported in patients treated with ixazomib, commo nly in the setting of 
the previously  noted gastrointestinal toxicit ies and dehydrat ion.
Fluid deficit should be prompt ly corrected before administration of study drug and as needed 
during treatment to avoid dehydrat ion.
Hypotension
Symptom atic hypotensio n and orthostatic hypotension wit h or without syncope have been 
reported wi th ixazo mib. Blood pressure should be closely mo nitored as per standard of care while 
the pati ent is on study  treatm ent, and fluid deficit should be corrected as needed, especially in the 
setting of conco mitant symptom s such as nausea, vomit ing, diarrhea, or decreased appetite. 
Patients taking m edicati ons or di uretics to manage their blood pressure (for either hypotension or 
hypertensio n) should be managed according to standard clinical practice, including considerat ions 
For non-commercial use only
Ixazomib
Study No. C16027 Page 27of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALfor dose adj ustments of their conco mitant m edicat ions during the course of the trial. Fluid deficit 
shoul d be corrected before administration of study  drug and as needed during treatment to avoid 
dehydrat ion.
Posterior Reversible Encephalopathy Syndrome
Posterior reversible encephalopathy s yndro me, which ult imately reso lved, has been reported with 
ixazo mib. This condit ion is usually transient and reversible. It is characterized by headache, 
seizures, and visual loss, and abrupt increase in blo od pressure. Diagnosis may  be confirmed by  
magnet ic resonance imaging or computed tomography. If the syndrome is diagnosed or suspected, 
symptom -directed treatm ent shoul d be m aintained unt il the condit ion is reversed by control of 
hypertensio n or other inst igating factors.
Transverse Myelitis
Transverse myelit is has been reported with ixazo mib. It is not known whether ixazo mib causes 
transverse myelit is; however, because transverse myelit is happened to a patient receiving 
ixazo mib, the possibilit y that ixazomib may have contributed to the transverse myeli tis cannot be 
excluded. Transverse myelit is should be managed according to standard medical practice.
Overdose
An overdose is defined as a known deliberate or accidental administration of invest igational drug, 
to or by a study subject, at a dose above that which is assigned to that individual subject according 
to the study  protocol . Overdose has been reported in patients taking ixazo mib. Symptoms of 
overdose are generally consistent with the known risks of ixazo mib. Reports of accidental 
overdose have been associ ated wi th serious adverse events, such as nausea, lung infect ions 
including aspiration pneumo nia, m ultiple organ failure, and death. If overdose occurs, consider 
close observati on including hospitalizat ion for hemodynamic support. Gastric lavage may be 
considered if inst ituted wi thin 1 hour of ingest ion of ixazo mib overdose.
AEs associ ated wi th an overdose will be documented on AE eCRF according to Section 10.0, 
Adverse Events. SAEs associated with overdose should be reported according to the procedure 
outlined in Sect ion10.2, Collect ion and Reporting of SAEs.
8.7.2 Management of Combination Therapy Clinical Events
For each medicat ion(s) used as co mbinat ion therapy with or without ixazomib, please refer to the 
prescribing information and details in the parent protocol for the applicable managemen t of 
clinical events. 
8.8 Blinding and Unblinding
This is an open -label study .
8.9 Description of Investigational Agents
The ixazo mib capsule formulat ion consists of the drug substance (ixazomib citrate), 
microcrystalline cellulo se, tal c, and magnesium stearate. There are 7 capsule strengths: 0.2, 0.5, 
For non-commercial use only
Ixazomib
Study No. C16027 Page 28of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIAL2.0, 2.3, 3.0, 4.0, and 5.5 mg. Each strength is different iated by  a uniq ue capsule size and co lor. 
Dosage strength is stated as ixazo mib. Ixazo mib capsules are individually  packaged in blisters.
For addi tional details, pl ease see the ixazo mib IB and Pharmacy Manual.
8.10 Preparation, Reconstitution, and Dispensation
The 0.2, 0.5, a nd 2.0 mg ixazo mib capsules (B1 formulat ion) are supplied in 1×4 blister strips that 
are individually perforated. The strips are placed in cartons containing 6 strips (24 total capsules) 
of the sam e strength . 
The 2.3, 3.0, 4.0 , and 5.5 mg ixazo mib capsule s (B2 formulat ion) are individually packaged using 
cold form foil-foil blisters that are in a child -resistant carton. There are 3 capsules (of exact 
strength) in each carton. 
8.11 Packaging and Labeling
Ixazo mib st udy drug will be provided by Takeda . The study drug labels will fulfill all requirements 
specified by governing regulations. 
8.12 Storage, Handling, and Accountability
On receipt at the invest igative site, ixazo mib should remain in the blister pack and carton provided 
until use or dispensat ion. The contai ner should be stored as directed by the label on the packaging. 
All excursio ns should immediately be brought to the sponsor’s attention for assessment and 
authori zation for continued use. Ensure that the drug is used before the retest expiry date provided 
by Takeda . Expi ry extensi ons will be co mmunicated accordingly wit h updated documentation to 
support the extended shelf life.
Ixazo mib dispensed to the patient for take -home dosing should remain in the blister packaging and 
carton and stored as directed by  the label  on the packaging as noted previously  until  the point of 
use. Patients who are receiving take -home medicatio n shoul d be given a supply o f study  drug as 
per the parent study  schedule or for up to 3 cycles at the discretion of the invest igator. (Not e: 
Patients in France are only permitted to receive 1 cycle of medicat ion at a time). In case of the 
COVID -19 pandemic prevent ing a patient fro m attending the study  site, si tes may  use al ternat ive 
strategies to deliver study drug to patients (eg, via couri er or si te staff), per local standard practice 
and regulations and wit h prior approval  from the investi gator and the sponsor’s project 
clinician/designee. Com prehensive instructions should be provided to the patient to ensure 
compliance wi th, and understan ding of, dosing procedures and to avoid the potential for incorrect 
self-administrati on or overdose of medication. 
Patients shoul d be instructed to store the medicat ion as directed by  the l abel on the packaging. 
Patients should be instructed to return the ir empty or partially used cartons to the investigative site 
at thei r next visit, rather than discarding them, as permitted by  site policy. Reconciliat ion will 
occur accordingly when the patient returns at their next visit for take -home medicat ion. In case of 
the COVID -19 pandemic prevent inga pat ient from attending the study site, drug packs and dosing 
For non-commercial use only
Ixazomib
Study No. C16027 Page 29of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALdiaries shoul d be returned at the next available on -site clinic visi t. Any  excursi ons in tem perature 
shoul d be reported and deal t with on a case -by-case bas is. 
Ixazo mib is an ant icancer drug and, as with other potentially toxic co mpounds, caution should be 
exercised when handling the study  drug. Patients should be instructed not to chew, break, or open 
capsules. In case of contact with broken capsules, raisi ng dust should be avo ided during the 
clean-up operati on. The product m ay be harmful by  inhalat ion, ingest ion, or skin absorption. 
Gloves and protecti ve cl othing shoul d be worn during clean -up and during return of broken 
capsules and powder to minimize skin contact. The area should be vent ilated and the site washed 
with soap and water after material pick up is co mplete. The material should be disposed of as 
hazardous medical waste in co mpliance with federal, state, and local regulat ions. 
In case of contact with the powder (eg, from a broken capsule), skin should be washed 
immediately  with soap and copi ous am ounts of water for at least 15 minutes. In case of contact 
with the ey es, copi ous am ounts of water should be used to flush the ey es for at l east 15 minut es. 
Medical personnel should be notified.
Patients are to be instructed on proper storage, accountabilit y, and administrati on of  ixazo mib, 
including that study  drug i s to be taken as intact capsules.
Please refer to the Pharmacy  Manual for this study for a dditional instructi ons.
8.13 Combination Therapy
Patients who entered the study receiving a combination therapy wit h ixazo mib or with other study 
medicat ions will continue to receive the combinat ion regimen.
The m edicati on(s) used in combinat ion with ixazomib o r the control  arm treatm ents m ay be 
site-sourced from commercial supply wit h commercial packaging and labeling when arrangements 
have been made and agreed to by  Takeda and the clinical site and when regulations allo w for 
clinical site sourcing, appropriate labeling, and compliance wit h local and regi onal regulati ons. 
The m edicati on(s) may  be provi ded by the sponsor if the site is unable to obtain these drugs from 
commercial sources. 
Addit ional details are provided in the package insert (PI) /summary  of product characteristics 
(SmPC) f or the applicable medicat ion(s) used in the parent study . 
8.14 Other Protocol -Specified Materials
No other drugs or ancillary  material are supplied for use in this study .
9.0 STUDY CONDUCT
This tri al will be conducted in com pliance wi th the protocol, Good Clinical Pract ice (GCP), 
applicable regulatory  requi rements, and Internat ional Conference on Harmonisat ion (ICH) 
guidelines.
For non-commercial use only
Ixazomib
Study No. C16027 Page 30of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIAL9.1 Study Personnel and Organizations
The contact informat ion for the Medical Monitor for this study , and any additional clinical 
laboratories, the coordinat ing invest igator for each member state/country , and other vendors as 
necessary , such as the interactive voice response system (IVRS)/interactive web response system 
(IWRS) provider, and the contract research o rganization (CRO) team may be found in the Study  
Manual. A full list of investigators is available in the sponsor’s invest igator database.
9.2 Arrangements for Recruitment of Patients
Patients will  only  be consi dered f or this study  if they were enrolled in 1 of the parent studi es.The 
transfer of patients between sites is allowed with the approval o f the sponsor’s clinician/designee 
(eg, in the case of site closure, patient moving, etc). No additional recruit ment activit y is needed.
9.3 Treatment Group Assignments
Patients will  enter this study  on the same dose, schedule of study  drug(s), and combinat ion 
regimen that they  were receiving at the time o f rollover fro m the parent study  (Secti on 8.1), or 
according to the required dose modificat ion from a parent study . For those pati ents who received 
ixazo mib based on BSA dosing per the parent study, the dose may be rounded. The dose may also  
be rounded for those pa tients who convert from BSA -based dosing to fixed dosing with approval 
from the Medical Monitor. No new anticancer agents can be started or added. Note that for patients 
whose study therapy in a parent study includes a placebo, the placebo capsule will be discontinued; 
crossover to ixazo mib is not permitted.
9.4 Study Procedures
In acknowl edgement of hospital, local, state or national government restrict ions, or other 
site-related factors caused by  the COVID -19 pandemic that may prevent investigators from 
condu cting the study  according to the Schedule of Events at the clinical study  site, invest igators 
may continue patients in the study despite departure fro m the Schedule of Events. Invest igators are 
expected to evaluate the impact to the safet y of the study  participants and site personnel for 
patients to con tinue. In evaluat ing such requests, the invest igator/study  site staff will give the 
highest pri ority to the safet y and welfare of the patients. Patients must be willing and able to 
continue taking study  medication and rem ain compliant wi th the protocol . For pati ents that are 
impacted by  the COVID -19 pandemic , any  procedures not conducted per the study  protocol  will 
be docum ented in the eCRF. 
Alternat ive methods should be considered for performing the assessme nts by other means than the 
patient presenting to the clinic (eg, remote assessment, having lab assessment performed at a 
facilit y closer to the pati ent’s home, etc.) If a patient misses an in -person study  visit, the 
investigator/study  team staff will spea k direct ly with the patient by telephone or other medium (eg, 
a com puter -based video communicat ion) during each visit window to assess subject safety  and 
overall clinical status. During this contact with the patient, the study  site physician or other 
quali fied site staff should at minimum conduct AE collect ion and an assessment of clinical 
symptoms. Other study  assessments m ay be collected rem otely as i s feasible and may  involve 
For non-commercial use only
Ixazomib
Study No. C16027 Page 31of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALaudio or vi deo recording. Assessments/procedures that cannot be completed durin g the 
protocol -specified window because a site visit is done remotely (eg, hematology , clinical 
chemistry , concomitant m edicat ions/procedures) are waived. 
Refer to the Schedule of Events ( Appendix A) for timing of assessments. Procedures performed at 
the end of treatment (EOT)/EOS in the patient’s parent study  and co llected in the eCRFs within 
28days of the study  entry /Day 1 visit do not need to be repeated. 
Addit ional details are provided as necessary  in the sect ions that fo llow.
9.4.1 Informed Consent
Each patient must provide written informed consent before any  study -requi red procedures are 
conducted, unless those procedures are performed as part of the patient’s standard care.
Patients previ ously  enrolled in this study  who remain on study  treatm ent upon implementation o f 
Amendment 3 may need to be reconsented, according to IRB/IEC standards. Reconsent ing should 
be done in person, where possible. Remote reconsent ing is per mitted as long as the process adheres 
to site, IRB/IEC, and GCP standards and local regulat ions.
9.4.2 Vital Signs
Vital sign m easurements include measurements of diastolic and systolic blood pressure and heart 
rate.
9.4.3 Weight
Weight will be measured at the Study  Entry / Day  1 visi t and at the EOS vi sit.
9.4.4 Pregnancy Test
A ser um pregnancy  test will be performed for women of childbearing potential at the Study Entry / 
Day 1 visit before the first dose of study drug and at the EOS visit. The serum pregnancy test may 
be co mpleted within 28 days of the Study  Entry /Day  1 Visi t. The r esults must be available and 
negat ive before the study  drug regimen is administered. Pregnancy tests may also be repeated 
during the study if requested by an independent ethics committee (IEC)/inst itutional review board 
(IRB) or if required by local regula tions or the prescribing information for any medicat ion(s) used 
as combinat ion therapy  with ixazomib.
Pregnancy prevention measures as per the parent study  shoul d continue to be used.
9.4.5 Concomitant Medications and Procedures
Only concomitant medicat ions and therapeuti c procedures related to the treatment of AEs that are 
reported in the study eCRFs (see Section 10.2) will be recorded in the eCRFs as spe cified in the 
Schedule of Events Appendix A. See Secti on 8.4and Section 8.5for a list of medications and 
therapi es that are prohibited and/or allowed during the study .
For non-commercial use only
Ixazomib
Study No. C16027 Page 32of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIAL9.4.6 Adverse Events
Moni toring of AEs, serious and nonserious, will be conducted throughout the study as specif ied in 
the Schedule of Events Appendix A. Ref er to Section 10.0 for details regarding definit ions, 
docum entati on, and reporting of AEs and SAEs.
SAEs, ≥Grade 3 AEs, ≥Grade 2 peripheral neuropathy , new primary malignancies, any  AE 
resul ting in dose modification or discontinuation of any study drug , orany other AE that in the 
opinio n of the invest igator is a clinically significant event will be recorded in the eCRFs and SAEs 
will also be reported direct ly to the sponsor (see Section 10.2)
. The AEs meeting the definit ions 
above that are ongoing at the time of entry into the rollover study will be recorded in the eCRFs as 
baseline AEs .
9.4.7 Enrollment
A pat ient is considered to be e nrolled in the study when he/she has received the first dose of study 
drug in this rollover study .
Procedures for completion of the enrollment informat ion are described in the Study  Manual.
9.4.8 Clinical Laboratory Evaluations
Clinical laboratory  evaluat ions will be perform ed locally. Local  laboratory  norm al ranges will be 
entered in the eCRFs.
9.4.8.1 Clinical Chemistry, Hematology, and Urinalysis
Blood sam ples f or analysis of the clinical chemistry  and hematol ogical parameters shown in 
Table 9.awill be obtained and recorded in the eCRFs as specified in the Schedule of Events 
Appendix A
.
Table 9.a Clinical Chemistry and Hematology Tests
Hematology Serum Chemistry
Hematocrit
Hemoglobin
Leukocytes with differential
Neutrophils ANC
Platelet (count)Albumin
Alkaline phosphatase (ALP)
Alanine aminotransferase (ALT)
Aspartate aminotransferase (AST)
Bilirubin (total)
Blood urea nitrogen (BUN)
Calcium
Carbon dioxide (CO 2)a
CreatinineChloride
Gamma glutamyl transferase (GGT)
Glucose
Lactate dehydrogenase (LDH)
Magnesium
Phosphate
Potassium
Sodium
Urate
aIf CO 2is not done as a part of standard care in the participant’s region, then this test does not need to be performed.
For non-commercial use only
Ixazomib
Study No. C16027 Page 33of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIAL9.4.9 Disease Assessment
It is recommended that disease assessments are performed per standard of care. An overall 
investigator assessment of best response obtained during this rollo ver study  and the invest igator 
assessment of date of progression will be recorded in the eCRF at th e EOS visit.
9.5 Completion of Study (for Individual Patients)
Patients will  be considered to have completed the study  if they are discont inued fro m study  
treatm ent for any  reason.
9.6 Withdrawal of Patients From Study
A pat ient will be withdrawn fro m the study  for any of the fo llowing reasons:
Progressive disease (as defined in the pat ient’s parent study ). 
Pregnancy.
Transit ion to commercial supply of study  drug(s).
Study  terminated by  sponsor.
Withdrawal by subject.
Lost to follow -up.
Death.
A pat ient may also be withdrawn fro m the study  for any  of the f ollowing reasons:
Adverse event.
Protocol  deviat ion. 
Clinical deterioration, in the investigator’s opinio n.
Invest igator’s decisio n.
Other.
The consequence of study  withdrawal  is that no new informat ion will be collected from the 
withdrawn pati ent and added to the exist ing data or any database.
9.7 Study Compliance
Study  drug will be administered or dispensed only to eligible pat ients under the supervisio n of the 
investigator or ident ified subinvest igator(s). The app ropri ate study personnel will maintain records 
of study  drug recei pt and dispensing.
For non-commercial use only
Ixazomib
Study No. C16027 Page 34of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIAL10.0 ADVERSE EVENTS
10.1 Definitions
10.1.1 Adverse Event Definition
AE means any untoward medical occurrence in a patient or subject administered a pharmaceut ical 
product; the untoward me dical occurrence does not necessarily have a causal relat ionship wit h this 
treatm ent. An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory  finding), symptom, or disease temporally  associ ated wi th the use of a m edicin al 
(invest igational) product whether or not it is related to the medicinal product. This includes any 
newly occurring event, or a previous condit ion that has increased in severit y or frequency since the 
administration of study  drug.
An abnormal laboratory  value will not be assessed as an AE unless that value leads to 
discontinuat ion or delay in treatment, dose modification, therapeutic intervent ion, or is considered 
by the investigator to be a clinically significant change fro m baseline.
10.1.2 Serious Adverse Eve nt Definition
SAE m eans any untoward medical occurrence that at any  dose:
Results in death.
Is life-threatening (refers to an AE in which the patient was at risk of death at the time of the 
event. It does not refer to an event which hypothetically might ha ve caused death if it were 
more severe).
Requi res inpat ienthospitalization or prolongation of an existing hospitalization (see 
clarificati onin the paragraph in Sect ion 10.2 on planned hospitalizat ions).
Results in persistent or significant disability or incapacity . (Disabilit y is defined as a 
substant ial disrupt ion of a person’s abilit y to conduct normal life functions).
Is a congenital anomaly/birth defect .
Is a medically important event . This refers to an AE that may  not resul t in death, be 
immediately  life threatening, or require hospitalization, but may be considered serious when, 
based on appropriate medic al judgment, may  jeopardi ze the pati ent, requi re medical or 
surgi cal interventi on to prevent 1 of the outcomes listed above, or involves suspected 
transmissio n via a medicinal product of an infect ious agent. Examples of such medical events 
include allergic bronchospasm requiring intensive treatment in an emergency room or at home, 
blood dyscrasias or convulsio ns that do not result in inpatient hospitalizat ion, or the 
development of drug dependency  or drug abuse; any  organism , virus, or infecti ous parti cle 
(eg, prion protein transmitt ing transmissible spongiform encephalopathy), pathogenic or 
nonpathogenic, is considered an infect ious agent.
In thi s study , intensi ty for each AE, including any  lab abnormalit y, will be determined using the 
NCI CTCAE, Versi on5.0, effective date 27 November 2017 [1].Clarificat ion should be made 
For non-commercial use only
Ixazomib
Study No. C16027 Page 35of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALbetween an SAE and an AE that is considered severe in intensit y (Grade 3 or 4), because the terms 
serious and severe are NOT synony mous. The general  term  severe is often used to describe the 
intensity (severi ty) of a specific event; the event itself, however, may  be of  relatively minor 
medical significance (such as a Grade 3 headache). This is NOT the same as serious , which is 
based o n patient/event outcome or action criteria described above, and is usually associated with 
events that pose a threat to a patient’s life or abilit y to functi on. A severe AE (Grade 3 or 4) does 
not necessarily need to be considered serious. For example, a w hite blood cell count of 1000/mm3
to less than 2000 i s considered Grade 3 (severe) but may not be considered serious. Seriousness 
(not intensit y) serves as a guide for defining regulatory  reporti ng obligat ions.
10.2 Procedures for Recording and Reporting Advers e Events and Serious 
Adverse Events
The fo llowing AEs spontaneously  reported by  the pati ent and/or in response to an open question 
from study  personnel or revealed by observat ion, physical examinat ion, or other diagnostic 
procedures will be recorded on the appropri ate page of the eCRF (see Sect ion10.3 for the period 
of observati on). 
All SAEs (see Sect ion 10.1.2 ).
All ≥Grade 3 AEs (see Section 10.1.2 ).
≥Grade 2 peripheral neuropathy .
New primary malignancies. 
Any AE result ing in dose modificat ion or discont inuat ion of any  study  drug.
Any other AE that in the opinio n of the invest igator is a clinically significant event. 
Any clinically  relevant deteri oration in laboratory  assessments or other clinical finding is 
considered an AE, but should only be recorded in eCRF if meet ing any of the above criteria . Whe n 
possible, signs and symptoms indicat ing a commo n underlying patho logy shoul d be noted as 1 
comprehensive event.
Regardless of cau sality, SAEs (as defined in Sect ion
 10.1) must be reported (see Section 10.3 for 
the period of observation) by the investigator to the Takeda Global Pharmacovigilance depart ment 
or desi gnee (contact informat ion provi ded bel ow). This shoul d be done by  faxing the SAE Form 
within 24 hours after bec oming aware of the event. The SAE Form, created specifically by Takeda, 
will be provided to each clinical study site. A sample of the SAE Form may be found in the Study 
Manual. Follow- up informat ion on the SAE may be requested by Takeda. SAE report informa tion 
must be consistent with the data provided on the eCRF.
The paper SAE forms must be submitted via fax (see fax numbers below) within 24 hours of 
awareness. In case of fax, site personnel must confirm successful transmissio n of all pages and 
include an e-mail address on the fax cover sheet so that an acknowledgment of receipt can be 
returned via e -mail wit hin 1 business day. E -mail submissi on of paper SAE form s with a PDF 
attachment should only  be used in the case where fax is not possible within 24 hour s of receiving 
For non-commercial use only
Ixazomib
Study No. C16027 Page 36of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALthe event. In case of e -mail, site personnel must confirm successful transmissio n by await ing an 
acknowledgment of the receipt via e -mail wit hin 1 business day. If SAEs are reported via fax or by 
e-mail, the EDC applicat ion must be updated a s soon as possible with the appropriate informat ion.
SAE Reporting Contact Information
Cognizant
US and Canada
Toll-Free Fax #: 1 -800-963 -6290
E-mail: takedaoncocases@cognizant.com
All Other Countries (Rest of World)
Fax #: 1-202-315-3560
E-mail: takedaoncocases@cognizant.com
Planned hospital admissio ns or surgical procedures for an illness or disease that existed before the 
patient was enrolled in the trial are not to be considered AEs unless the condit ion deteriorated in an 
unexpected manner dur ing the trial (eg, surgery  was perform ed earlier or l ater than planned).
For both serious and nonserious AEs, the invest igator must determine both the severit y (toxi city 
grade) of the event and the relat ionship of the event to study drug administration. 
Severit y (toxi city grade) for each AE, including any  laboratory  abnorm ality, will  be determined 
using the NCI CTCAE, Version 5.0, effect ive date 27 November 2017 [1]. The cri teria are 
provi ded in the S tudy Manual.
Relationship of the event to study drug administration (ie, its causalit y) will be determined by the 
investigator responding y es (rel ated) or no (unrelated) to this quest ion: “Is there a reasonable 
possibilit y that the AE is associated with the study  drug?”
10.3 Monitoring of Adverse Events and Period of Observation
AEs meet ing the criteria in Sect ion
 10.2 must be reported to the sponsor as follows:
AEs will be reported from the first dose of study  drug for this study  through 30 days after 
administration of the last dose of study  drug and recorded i n the eCRFs. AEs meet ing the 
criteria in Section 10.2 that are ongoing at the time of entry into the rollo ver study  will be 
recorded in the eCRFs as baseline AEs .
AEs meet ing the criteria in Sect ion 10.2 will be fo llowed until reso lution, unt il the AE 
beco mes chroni c or stable, or i s determined to be part of the underlying disease process, or 
until the pat ient attends the EOS visit and discontinues the study. 
For non-commercial use only
Ixazomib
Study No. C16027 Page 37of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALSAEs
–Related and unrelated treatment -emergent SAEs will be reported to the Takeda Global 
Pharmacovigilance department or designee fro m the first dose of study  drug through 
30days after administration o f the last dose of study drug and recorded in the eCRF. After 
this peri od, only related SAEs m ust b e reported to the Takeda Global Pharmacovigilance 
departm ent or desi gnee. SAEs shoul d be m onitored until they  are resolved or are clearly 
determined to be due to a patient’s stable or chronic condit ion or intercurrent illness(es).
10.4 Procedures for Reporting Drug Exposure During Pregnancy and Birth Events
If a woman beco mes pregnant or suspects that she is pregnant while participat ing in this study, she 
must inform the invest igator immediately and permanent ly discont inue study  drug. The sponsor 
must al so be co ntacted immediately by faxing a completed Pregnancy Form to the Takeda Global 
Pharmacovigilance department or designee (see Section 10.2). The pregn ancy m ust be f ollowed 
for the final pregnancy  outcom e.
If a female partner of a male patient becomes pregnant during the male pat ient’s participat ion in 
this study, the sponsor must also be contacted immediately by faxing a completed Pregnancy Form 
to the Takeda Gl obal Pharmacovigilance depart ment or designee (see Sect ion 10.2). Every  effort 
shoul d be made to follow the pregnancy for the final pregnan cy outcom e.
10.5 Procedures for Reporting Product Complaints or Medication Errors (Including 
Overdose)
A product complaint is a verbal, written, or electronic expression that implies dissat isfaction 
regarding the identit y, strength, puri ty, quali ty, or s tabilit y of a drug product. Individuals who 
ident ify a potential product complaint situat ion shoul d immediately report to: 
ctmcomplaint@takeda.com.
Product complaint s in and of themselves are not AEs. If a product complaint results in an SAE, an 
SAE Form should b e com pleted and sent to Cognizant (refer to Section 10.2).
A medicat ion error is a preventable event that involves an ident ifiable pat ient and that leads to 
inappropriate medicat ion use, which may  resul t in patient harm. Whereas overdoses and 
underdoses const itute medication errors, doses missed inadvertent ly by a pat ient do not. 
Individuals who ident ify a potential medicat ion error (including overdos e) situation should 
immediately  report thi s to Cogni zant ( refer to Section
 10.2). 
10.6 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities
The sponsor will be responsible for reporting all suspected unexpected serious adverse react ions 
(SUSARs) and any other applicable SAEs to regulatory  authori ties, including the European 
Medicines Agency, invest igators and IRBs or IECs, as applicable, in accordance with nat ional 
regul ations in the countries where the study  is conducted. Relat ive to the first awareness of the 
event by/or further provisio n to the sponsor or sponsor’s designe e, SUSARs will be submitted to 
the regulatory  authorit ies as an expedited report within 7 days for fatal and life -threatening events 
For non-commercial use only
Ixazomib
Study No. C16027 Page 38of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALand 15 days for other serious events, unless otherwise required by nat ional regulat ions. The 
sponsor will also prepare an e xpedited report for other safet y issues where these might materially 
alter the current benefit -risk assessment of an investigat ional medicinal product or that would be 
sufficient to consider changes in the investigat ional medicinal product’s administration or in the 
overall conduct of the trial. The invest igational site also will forward a copy  of all expedited 
reports to his or her IRB or IEC in accordance wit h national regulat ions. 
11.0 STUDY- SPECIFIC COMMITTEES
No steering committee, data safety  monitoring c ommi ttee, or clinical endpoint committee will be 
used in this study .
12.0 DATA HANDLING AND RE CORDKEEPING 
The full details of procedures for data handling will be documented in the Data Management Plan. 
If selected for coding, AEs and concurrent conditions wil l be coded using the Medical Dictionary  
for Regul atory  Activit ies (MedDRA). Drugs will be coded using the World Health Organizat ion 
(WHO) Drug Dictionary .
12.1 eCRFs
Com pleted eCRFs are required for each subject who signs an informed consent form.
The sponsor o r its designee will supply invest igative sites with access to eCRFs and will make 
arrangements to train appropriate site staff in the use of the eCRF. These forms are used to transmit  
the informat ion collected in the performance of this study  to the sponso r, CRO partners, and 
regul atory  authori ties. Invest igative sites must complete eCRFs in English.
After complet ion of the entry process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing data, and questionable values. Queri es may  be issued by Takeda 
personnel (or designees) and will be answered by the site.
Any change of, modificat ion of, or addit ion to the data on the eCRFs should be made by the 
investigator or appropriate site personnel . Corrections to eCRFs are recor ded in an audit trail that 
captures the old informat ion, the new information, ident ificat ion of the person making the 
correcti on, the date the correction was made, and the reason for change.
The principal invest igator must review the eCRFs for completenes s and accuracy  and must si gn 
and date the appropriate eCRFs as indicated. Furthermore, the principal invest igator must retain 
full responsibilit y for the accuracy  and authent icity of all data entered on the eCRFs .
eCRFs will be reviewed for completeness an d acceptabilit y at the study  site during peri odic visi ts 
by study  monitors. The sponsor or i ts designee will be permitted to review the subject’s medical 
and hospital records pertinent to the study to ensure accuracy of the eCRFs. The completed eCRFs 
are the sole property  of the sponsor and should not be made available in any form to third parties, 
except for authorized representatives of appropriate governmental healt h or regulatory authorities, 
without wri tten permissio n of the sponsor.
For non-commercial use only
Ixazomib
Study No. C16027 Page 39of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIAL12.2 Record Retention
The invest igator agrees to keep the records stipulated in Section 12.1 and those documents that 
include (but are not limited to) the study -specific docum ents, the i dentificat ion log of all 
participat ing subjects, medical records, temporary media such as thermal sensit ive paper, source 
worksheets, all original signed and dated informed consent forms, subject authorizat ion forms 
regarding the use of pers onal health information (if separate from the informed consent forms), 
electroni c copy  of eCRFs, incl uding the audi t trail, and detailed records of drug disposit ion to 
enable evaluat ions or audits from regulatory  authori ties, the sponsor or its designees. Any source 
docum entati on printed on degradable thermal sensitive paper should be photocopied by the site 
and filed wit h the original in the subject’s chart to ensure long term legibilit y. Furtherm ore, ICH 
E6 Secti on 4.9.5 requi res the investigator to retai n essent ial docum ents specified in ICH E6 
(Secti on8) until at least 2 y ears after the last approval of a market ing applicat ion for a specified 
drug indicat ion being investigated or, if an applicatio n is not approved, until at least 2 years after 
the inves tigation is discontinued and regulatory authorities are notified. In addit ion, ICH E6 
Secti on4.9.5 states that the study  records should be retained unt il an am ount of time specified by  
applicable regulatory  requi rements or for a time specified in the Clin ical Study  Site Agreement 
between the invest igator and sponsor.
Refer to the Clinical Study Site Agreement for the sponsor’s requirements on record retention. The 
investigator should contact and receive written approval fro m the sponsor before disposing of any 
such documents.
13.0 STATISTICAL METHODS
13.1 Statistical and Analytical Plans
A stati stical analysis plan (SAP) will be prepared and finalized prior to database lock. This 
docum ent will provi de further details regarding the definit ion of analysis variables and analysis 
methodol ogy to address all study  objectives.
A data review will be conducted prior to database lock. This review will assess the accuracy and 
completeness of the study  database, subject evaluabilit y, and appropri ateness of the planned 
statist icalmethods.
13.1.1 Analysis Sets
The full analysis set (FAS) will included all enrolled patients who receive at least 1 dose of study  
medicat ion and will be used for the safet y analyses.
13.1.2 Efficacy Analysis
No efficacy  analyses are pl anned f or thi s study  as there is no statistical hypothesis testing.
The overall invest igator assessment of best response obtained during this rollo ver study  and 
investigator assessment of date of progression will be listed.
For non-commercial use only
Ixazomib
Study No. C16027 Page 40of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIAL13.1.3 Safety Analysis
The fo llowing AEs will be summarized with descrip tive stati stics for all  patients who receive at 
least 1 dose of ixazo mib using the FAS: 
All SAEs.
All ≥Grade 3 AEs. 
≥Grade 2 peripheral neuropathy .
New primary malignancies. 
Any AE result ing in dose modificat ion or discont inuat ion of any  study  drug.
Any other AE that in the opinio n of the invest igator is a clinically significant event. 
No formal stati stical testing or inferent ial stati stics will be generated.
All AEs will be coded using the current MedDRA versio n at the time of the analysis. Data will b e 
summarized using preferred term and primary  system organ cl ass. Local  laboratory  assessment 
changes and vital sign changes fro m study  entry  to end of study  will also be summarized.
Exposure to study  drug and study  regimen will be tabulated. In addition, reasons for drug 
discontinuat ion will  be summarized. 
Concomitant medicat ions and procedures related to treatment of AEs fro m screening through the 
end of study  will be classified by  generi c term s according to the WHO drug dict ionary. 
Data will be present ed by  the entire ixazo mib safety populat ion, by populat ion of monotherapy  of 
ixazo mib, and by populat ion of ixazo mib in co mbinat ion with other anti cancer agents(s) as 
specified in the SAP. Safet y listings will be prepared for patients receiving other study drugs and 
not ixazo mib. Addit ional safet y analyses by subgroups such as drug indication and baseline 
characterist ics may be perform ed as specified in the SAP. 
13.2 Interim Analysis and Criteria for Early Termination
No interim analysis is planned.
13.3 Determination of Sample Size
There is no statist ical hypothesis and no power considerat ions in this study. The number of patients 
will be determined as discussed in Sect ion 6.2.
14.0 QUALITY CONTROL AND QUALITY ASSURANCE
14.1 Study -Site Monitoring Visits
The study  site will be monitored remotely by the CRO periodically during the study to ensure that 
all aspects of the protocol are fo llowed. Moni toring will inc lude electronic data collect ion, which 
has a set of automat ic data checks with data queries for programmed data collect ion. There will be 
For non-commercial use only
Ixazomib
Study No. C16027 Page 41of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALmonitoring of study  site by  telephone and email to ensure that the drug supplies have been 
provi ded to the si te and pa tients and that protocol instructions are well understood and applied.
Moni toring visit s to the study site will also be made periodically during the study to ensure that all 
aspects of the protocol are fo llowed. Source documents will be reviewed for verifi cation of data 
recorded on the eCRFs. Source documents are defined as original documents, data, and records. 
The invest igator and inst itution guarantee access to source documents by  the sponsor or i ts 
designee (CRO) and by  the IRB or IEC.
All aspects of the study and its documentation will be subject to review by the sponsor or designee, 
including but not limited to the Invest igator’s Binder, study  medicat ion, subject medical records, 
inform ed consent docum entati on, docum entati on of  subject authorizat ion to use personal 
inform ation (if separate fro m the inform ed consent form s), and review o f eCRFs and associated 
source documents. It is important that the invest igator and other study personnel are available 
during the monitoring visits and th at sufficient time is devoted to the process. 
In the event a monitor cannot visit the site in a timely manner due to the COVID -19 pandemic, 
alternat ive monitoring approaches such as remote source data verificat ion (SDV) or telephone 
contact m ay be used to ensure data qualit y and integrity  and maintain pat ient safet y. Alternative 
monitoring approaches should be used only  where all owed by  the l ocal Heal th Authori ty and 
permitted by  the IRB/IEC.
14.2 Protocol Deviations
The invest igator should not deviate fro m theprotocol , except where necessary  to eliminate an 
immediate hazard to study subjects. Should other unexpected circumstances arise that will require 
deviat ion from protocol -specified procedures, the investigator should consult with the sponsor or 
designee ( and IRB or IEC, as required) to determine the appropriate course of action. There will be 
no exempt ions (a prospectively approved deviat ion) from the inclusio n or exclusio n criteria.
The site should document all protocol deviat ions in the subject’s source docum ents. In the event of 
a significant devi ation, the si te shoul d notify  the sponsor or i ts desi gnee (and IRB or EC, as 
requi red). Si gnificant devi ations include, but are not limited to, those that invo lve fraud or 
misconduct, increase the health risk to the subject, or confound interpretation of primary study 
assessment. A Protocol Deviat ion Form  or equivalent form should be co mpleted by  the si te and 
signed by the sponsor or designee for any  significant deviation from the protocol.
14.3 Quality Assurance Audits and Regulatory Agency Inspections
The study  site also m ay be subject to qualit y assurance audi ts by  the sponsor or desi gnees. The 
investigator agrees to provide access to records, facilit ies, and personnel for conduct of any 
inspection or audit. If a qu ality assurance audit is requested, the sponsor -designated auditor will 
contact the site in advance to arrange an audit ing visit. The auditor may  ask to visi t the facilit ies 
where laboratory  samples are collected, where the medicat ion is stored and prepare d, and any  
other facilit y used during the study . In addi tion, there is the possibilit y that thi s study  may be 
inspected by regulatory agencies, including those of foreign governments (eg, the FDA, the United 
Kingdo m Medicines and Healt hcare products Regula tory Agency , the Pharmaceut icals and 
For non-commercial use only
Ixazomib
Study No. C16027 Page 42of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALMedical Devices Agency of Japan). If the study  site is contacted for an inspection by  a regulatory 
body , the sponsor should be notified immediately . The investi gator and inst itution guarantee 
access for qualit y assuranc e audi tors to all study  docum ents as described in Sect ion14.1.
15.0 ETHICAL ASPECTS OF T HE STUDY
This study  will be conducted wi th the highest respect f or the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration o f 
Helsinki, and the ICH Harmonised Tripart ite Guideline for GCP. Each investigator will conduct 
the study  according t o applicable local or regional regulatory requirements and align his or her 
conduct in accordance with the “Responsibilit ies of the Invest igator” that are listed in Appendix B. 
The principles of Helsinki are addressed through the protocol and through appendices containing 
requi rements for informed consent and invest igator responsibilities.
15.1 IRB and/or IEC Approval
IRBs and IECs must be constituted accordi ng to the applicable state and federal/local requirements 
of each participat ing regio n. The sponsor or designee will require documentation noting all names 
and tit les of members who make up the respective IRB or IEC. If any member of the IRB or IEC 
has di rect parti cipat ion in this study , written notification regarding his or her abstinence fro m 
voting must also be obtained. Those American sites unwilling to provide names and tit les of all 
members due to privacy  and conflict of interest concerns should inste ad provide a Federal Wide 
Assurance Number or comparable number assigned by the Department of Health and Human 
Services.
The sponsor or designee will supply relevant documents for submissio n to the respective IRB or 
IEC for the protocol’s review and approv al. This protocol , the Invest igator’s Brochure, a copy o f 
the informed consent form, and, if applicable, subject recruit ment materials and/or advertisements 
and other documents required by all applicable laws and regulations, must be submitted to a 
central or local IRB or IEC for approval. The IRB’s or IEC’s written approval of the protocol and 
subject informed consent must be obtained and submitted to the sponsor or designee before 
commencement of the study  (ie, before shipment of the sponsor -supplied drug or study  specific 
screening activit y). The IRB or IEC approval must refer to the study  by exact protocol tit le, 
number, and versio n date; ident ify versio ns of other documents (eg, informed consent form) 
reviewed; and state the approval date. The sponsor w ill ship drug/notify site once the sponsor has 
confirmed the adequacy of site regulatory  docum entati on and, when applicable, the sponsor has 
received permissio n from competent authori ty to begin the trial. Unt il the site receives 
drug/notificat ion no proto col activit ies, including screening may occur.
Sites m ust adhere to all requirements stipulated by  their respect ive IRB or IEC. This may include 
notification to the IRB or IEC regarding protocol amendments, updates to the informed consent 
form, recrui tmentmaterials intended for viewing by  subjects, l ocal safety  reporti ng requirements, 
reports and updates regarding the ongoing review of the study  at intervals specified by  the 
respective IRB or IEC, and submissio n of the investigator’s final status report to IRB or IEC. All 
IRB and IEC approvals and relevant documentation for these items must be provided to the 
sponsor or its designee.
For non-commercial use only
Ixazomib
Study No. C16027 Page 43of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALSubject incentives should not exert undue influence for participat ion. Payments to subjects must 
be approved by the IRB or IE C and sponsor.
15.2 Subject Information, Informed Consent, and Subject Authorization
Written consent documents will embody  the elements of informed consent as described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. The informed consent form, subject authorizat ion form (if 
applicable), and subject informat ion sheet (if applicable) describe the planned and permitted uses, 
transfers, and disclo sures of the subject’s personal and per sonal healt h informat ion for purposes of 
conducting the study. The informed consent form and the subject informat ion sheet (if applicable) 
further explain the nature of the study, its object ives, and potential risks and benefit s, as well as the 
date inform ed consent i s given. The informed consent form will detail the requirements of the 
participant and the fact that he or she is free to withdraw at any  time wi thout giving a reason and 
without prej udice to hi s or her further m edical care.
Patients previ ously enrolled in this study  who remain on study  treatm ent upon implementation o f 
Amendment 3 may need to be reconsented, according to IRB/IEC standards. Reconsenting should 
be done in person, where possible. Remote reconsent ing is per mitted as long as the proc ess adheres 
to site, IRB/IEC, and GCP standards and local regulat ions.
The invest igator is responsible for the preparation, content, and IRB or IEC approval of the 
inform ed consent form  and if applicable, the subject authorization form. The informed conse nt 
form, subject authorizat ion form (if applicable), and subject information sheet (if applicable) must 
be approved by both the IRB or IEC and the sponsor prior to use.
The informed consent form, subject authorizat ion form  (if applicable), and subject info rmation 
sheet (if applicable) must be written in a language fully co mprehensible to the prospective subject. 
It is the responsibilit y of the invest igator to explain the detailed elements of the informed consent 
form, subject authorizat ion form (if applicab le), and subject informat ion sheet (if applicable) to the 
subject. Information should be given in both oral and written form whenever possible and in the 
manner deemed appropriate by the IRB or IEC. In the event the subject is not capable of rendering 
adeq uate wri tten inform ed consent, then the subject’s legally  acceptable representative may 
provi de such consent for the subject in accordance with applicable laws and regulat ions.
The subject, or the subject’s legally acceptable representative, must be given ample opportunit y to: 
(1) inquire about details of the study and (2) decide whether or not to participate in the study. If the 
subject, or the subject’s legally acceptable representative, determines he or she will part icipate in 
the study , then the informe d consent form  and subject authorizat ion form (if applicable) m ust be 
signed and dated by  the subject, or the subject’s legally  acceptable representative, at the time of 
consent and prior to the subject entering into the study . The subject or the subject’s legally 
acceptable representative should be instructed to sign using their legal names, not nicknames, 
using blue or black ballpo int ink. The invest igator must also sign and date the informed consent 
form and subject authorizat ion (if applicable) at th e time of consent and prior to subject entering 
into the study; however, the sponsor may  allow a designee of the invest igator to sign to the extent 
permitted by  applicable law.
For non-commercial use only
Ixazomib
Study No. C16027 Page 44of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALOnce signed, the original informed consent form, subject authorization form (if ap plicable), and 
subject informat ion sheet (if applicable) will be stored in the invest igator’s site file. The 
investigator must document the date the subject signs the informed consent in the subject’s 
medical record. Copies of the signed informed consent f orm, the signed subject authorization for m 
(if applicable), and subject informat ion sheet (if applicable) shall be given to the subject.
All revised informed consent forms must be reviewed and signed by relevant subjects or the 
relevant subject’s legally  acceptable representative in the same manner as the original informed 
consent. The date the revised consent was ob tained shoul d be recorded in the subject’s medical 
record, and the subject should receive a copy  of the revised informed consent form.
15.3 Subject Confidentiality
The sponsor and designees affirm and upho ld the principle of the subject’s right to protection 
against invasio n of privacy. Throughout this study , a subject’s source data will only be linked to 
the sponsor’s clinical study  database or documentation via a unique ident ificat ion number. As 
permitted by all applicable laws and regulat ions, limited subject attributes, such as sex, age, or date 
of birth, and subject init ials may be used to verify the subject and accuracy o f the subject’s uniq ue 
ident ificat ion number.
To com ply with ICH Guidelines for GCP and to verify co mpliance with this protocol, the sponsor 
requi res the investigator to permit its monitor or designee’s monitor, representatives fro m any 
regul atory  authori ty (eg, FDA, Medi cines and Healt hcare products Regulatory  Agency, 
Pharmaceut icals and Medical Devices Agency), the sponsor’s designated auditors, and the 
appropriate IRBs and IECs to review the subject’s original medical records (source data or 
docum ents), including, but not l imited to, laboratory test result reports, ECG reports, admissio n 
and discharge summaries for hospital admissio ns occurring during a subject’s study participation, 
and autopsy  reports. Access to a subject’s original medical records requires the specific 
authorization of the subject as part of the informed consent process (see Section 15.2).
Copi es of  any subject source documents that are provided to th e sponsor m ust have certain 
personally ident ifiable informat ion rem oved (ie, subject name, address, and other ident ifier fields 
not collected on the subject’s [e]CRF).
15.4 Publication, Disclosure, and Clinical Trial Registration Policy
15.4.1 Publication 
The investi gator i s obliged to provide the sponsor with complete test results and all data derived by 
the invest igator from the study . During and after the study , only  the sponsor m ay make study  
inform ation available to other study  invest igators or to regulatory  agen cies, except as required by  
law or regul ation. Except as otherwise allowable in the clinical study  site agreement, any  public 
disclosure (including publicly accessible websites) related to the protocol or study  resul ts, other 
than study  recrui tment m aterials and/or advertisements, is the sole responsibilit y of the sponsor.
The sponsor may publish any data and informat ion fro m the study (including data and informatio n 
generated by  the invest igator) without the consent of the invest igator. Manuscript authorsh ip for 
For non-commercial use only
Ixazomib
Study No. C16027 Page 45of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALany peer -reviewed publicat ion will appropriately reflect contribut ions to the production and 
review of the document. All publicat ions and presentations must be prepared in accordance with 
this secti on and the Clinical Study  Site Agreement. In the ev ent of any discrepancy  between the 
protocol  and the Clinical Study  Site Agreement, the Clinical Study  Site Agreement will prevail.
15.4.2 Clinical Trial Registration
In order to ensure that informat ion on clinical trials reaches the public in a timely manner and to 
comply with applicable laws, regulat ions and guidance, Takeda will, at a minimum register 
intervent ional clinical tri als it sponsors anywhere in the worl d on ClinicalTrials.gov or other 
publicly  accessible websites on or before start of study , as define d in Takeda Policy/Standard. 
Takeda contact information, alo ng with invest igator’s cit y, state (for Am ericas invest igators), 
country , and recrui ting status will be registered and available for public viewing. 
As needed Takeda and Investigator/site contact information may be made public to support 
participant access to trials via registries. In certain situations/registries, Takeda may assist 
participants or potential participants to find a clinical trial by helping them locate trial sites closest 
to their homes by providing the investigator name, address, and phone number via email/phone or 
other m ethods callers requesting trial informat ion. Once subjects receive invest igator contact 
inform ation, they  may call the si te request ing enro llment into the trial. The invest igative sites are 
encouraged to handle the trial inquiries according to their established subject screening process. If 
the caller asks addit ional questions beyo nd the topic of trial enro llment, they should be referred to 
the sponsor. 
Any invest igator who objects to Takeda providing this informat ion to callers must provide Takeda 
with a wri tten noti ce request ing that their informat ion not be listed on the registry site. 
15.4.3 Clinical Trial Results Disclosure
Takeda will post the results of clinical t rialson ClinicalTrials.gov or other publicly  accessible 
websites (including the Takeda corporate site) and registries, as required by Takeda 
Policy/Standard, applicable laws and/or regulations. 
Data Sharing
The sponsor is committed to responsible sharing of clinical data with the goal of advancing 
medical science and improving pat ient care. Qualified independent researchers will be permitted 
to use data collected from pat ients during the study to conduct addit ional scient ific research, which 
may be unrela ted to the study  drug or the patient’s disease. The data provided to external 
researchers will not include informat ion that i dentifies pat ients personally.
15.5 Insurance and Compensation for Injury
Each subject in the study  must be insured in accordance with t he regulations applicable to the site 
where the subject is participat ing. If a local underwriter is required, then the sponsor or sponsor’s 
designee will obtain clinical study  insurance against the risk o f injury to clinical study subjects. 
Refer to the Cl inical Study  Site Agreement regarding the sponsor’s policy on subject 
For non-commercial use only
Ixazomib
Study No. C16027 Page 46of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALcompensat ion and treatment for injury. If the investigator has questions regarding this po licy, he or 
she should contact the sponsor or sponsor’s designee.
16.0 REFERENCES
1.Commo n Termino logy Criteria for Adverse Events (CTCAE) Version 5.0. U.S. Department of 
Health and Human Services, Nat ional Inst itutes of Health, National Cancer Inst itute. 
November 2017.
2.VELCADE (bortezomib) for Inject ion, October [package insert]. Ca mbridge, MA: 
Millennium Pharmaceuticals, Inc., October 2012.
3.NINLARO® (ixazo mib) capsules, for oral use [prescribing informat ion]. Cambridge, MA: 
Takeda Pharmaceutical Company  Limi ted.
4.Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. Oral Ixazo mib, 
Lenalido mide, and Dexamethasone for Mult iple Myelo ma. New England Journal of Medicine 
2016;374(17):1621 -
34.
For non-commercial use only
For non-commercial use only
Ixazomib
Study No. C16027 Page 48of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIAL(f) At EOS, record an overall investigator assessment of best response obtained during this rollover study and 
investigator assessment of date of progression.
(g) Vital sign measureme nts, which include measurements of diastolic and systolic blood pressure and heart rate, will 
be obtained at Study Entry/Day 1, EOS, and as medically needed at the discretion of investigator.
(h) Only concomitant medications and therapeutic procedures rela ted to the treatment of AEs that are collected in the 
study (see Section 10.2), will be recorded in the eCRFs.
(i) This will included collection of the following:
All SAEs .
All ≥Grade 3 AEs.
≥Grade 2 peripheral neuropathy.
New primary malignancies.
Any AE resulting in dose modification or discontinuation of study drug.
Any other AE that in the opinion of the investigator is a clinically significant event (see Section
 10.2).
(j) For all patients, hematology and chem istry laborato ry evaluations will be obtained at the Study Entry/Day 1 visit 
and at the EOS visit. Laboratory evaluations may be done within 4 weeks of the Study Entry/Day 1 visit. Unscheduled 
hematology and chemistry laboratory assessments may be performe d if clinically indicated. Laboratory samples will 
be processed locally.
(k) A serum -hCG pregnancy test will be performed only for women of childbearing potential. The serum pregnancy 
test may be completed within 28 days of the Study Entry /Day 1 visit. See Section 9.4.4 for additional details. 
Pregnancy tests may also be repeated during the study if required by an IEC/IRB or if required by local r egulations.
(l) Study drug(s) will be administered at the dose, schedule of study drug(s), and combination regimen that they were 
receiving at the time of rollover from the parent study, or according to the required dose modification from a parent 
study. For those patients who received ixazomib dosing based on body surface area (BSA) per the parent study, the 
dose may be rounded. The dose may also be rounded for those patients who convert from BSA -based dosing to fixed 
dosing with approval from the Medical Monitor. No new anticancer agents can be started or added. Note that for 
patients whose study therapy in a parent study includes a placebo, the placebo capsule will be discontinued; crossover 
to ixazomib is not permitted. Patients will continue to receive study treatment until disease progression, occurrence of 
an unacceptable toxicity, and/or other criteria as detailed in Section 9.6). Ixazomib and/ or other study drug(s) will be 
dispensed at each on -study visit (up to a 3 -cycle supply to the patient [eg, 21 -or 28 -day cycles] at the discretion of the 
investigator. Note: patients in France are only permitted to receive 1 cycle of medication at a time) . The study center 
staff will check the patient’s supply of remaining ixazomib tablets at each on -study visit to ensure proper compliance 
with dosing.
For non-commercial use only
Ixazomib
Study No. C16027 Page 49of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALAppendix BResponsibilities of the Investigator
Clinical research studies sponsored by  the sponsor are subject to ICH GCP and all the applicable 
local laws and regulat ions. The responsibilit ies imposed on invest igators by  the FDA are 
summarized in the “Statement of Invest igator” (Form FDA 1572), which must be completed and 
signed before the invest igator may participate in this study .
The invest igator agrees to assume the fo llowing responsibilit ies by signing a Form FDA 1572:
1.Conduct the study  in accordance wit h the protocol.
2.Personally conduct or supervise the staff who will assi st in the protocol.
3.Ensure that study related procedures, including study specific (non routine/non standard panel) 
screening assessments are NOT performed on potent ial subjects, prior to the receipt of written 
approval  from relevant governing bodies/autho rities.
4.Ensure that all co lleagues and emplo yees assist ing in the conduct of the study are informed of 
these obligat ions.
5.Secure prior approval o f the study and any changes by an appropriate IRB/IEC that conform to 
21 CFR Part 50, ICH, and local regulatory requi rements.
6.Ensure that the IRB/IEC will be responsible for init ial review, continuing review, and approva l 
of the protocol. Promptly report to the IRB/IEC all changes in research act ivity and all 
anticipated risks to subjects. Make at least y early repo rts on the progress of the study  to the 
IRB/IEC, and issue a final report within 3 months of study  com pletion.
7.Ensure that requirements for informed consent, as outlined in 21 CFR Part 50, ICH and local 
regul ations, are m et.
8.Obtain valid informed consent f rom each subject who participates in the study , and docum ent 
the date of consent in the subject’s medical chart. Valid informed consent is the most current 
versio n approved by the IRB/IEC. Each informed consent form should contain a subject 
authori zation section that describes the uses and disclosures of a subject’s personal 
inform ation (including personal health informat ion) that will take place in connect ion wit h the 
study . If an informed consent form does not include such a subject authorization, then th e 
investigator must obtain a separate subject authorization form from each subject or the 
subject’s legally acceptable representative.
9.Prepare and maintain adequate case histories of all persons entered into the study , incl uding 
eCRFs, hospital records, la boratory  resul ts, etc, and maintain these data for a minimum o f 
2years fo llowing notificat ion by the sponsor that all invest igations have been discont inued or 
that the regulatory  authori ty has approved the marketing applicat ion. The invest igator should 
contact and receive written approval fro m the sponsor before disposing o f any such 
docum ents.
10.Allow possible inspection and copying by the regulatory  authori ty of GCP -specified essent ial 
docum ents.
For non-commercial use only
Ixazomib
Study No. C16027 Page 50of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIAL11.Maintain current records of the receipt, administratio n, and disposi tion of  sponsor -supplied 
drugs, and return all unused sponsor -supplied drugs to the sponsor.
12.Report adverse reactions to the sponsor prompt ly. In the event of an SAE, notify the sponsor 
within 24 hours.
For non-commercial use only
Ixazomib
Study No. C16027 Page 51of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALAppendix CInvestigator Consent to Use of Personal Information 
Takeda will co llect and retain personal information of invest igator, including his or her name, 
address, and other personally identifiable informat ion. In addit ion, invest igator’s personal 
inform ation may be transferred to other parties located in countries throughout the world (eg, the 
United Kingdom, United States, and Japan), including the following:
Takeda, its affiliates, and licensing partners.
Business partners assist ing Takeda, its affiliates, and l icensing partners.
Regulatory  agencies and other health authorit ies.
IRBs and IECs.
Invest igator’s personal informat ion may be retained, processed, and transferred by  Takeda and 
these other parties for research purposes including the fo llowing:
Assessment of the sui tabilit y of invest igator for the study  and/or other clinical studies.
Management, monitoring, inspect ion, and audit of the study .
Analysis, review, and verificat ion of the study  results.
Safety reporti ng and pharmacovigilance relat ing to the study.
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies relat ing to other medications used in other clinical studies that may contain 
the sam e chemical com pound present in the study  medicat ion.
Inspect ions and invest igations by regulatory  authorit ies relat ing to the study.
Self-inspect ion and internal audit within Takeda, its affiliates, and licensing partners.
Archiving and audit of study  records.
Posting investigator site contact informat ion, study details and results on publicly accessible 
clinical trial registries, databases, and websites.
Invest igator’s personal inform ation may be transferred to other countries that do not have data 
protecti on laws that offer the same level of protection as data protection laws in invest igator’s own 
country .
Invest igator acknowledges and consents to the use of his or her personal inform ation by  Takeda 
and other parties for the purposes described above.
For non-commercial use only
Ixazomib
Study No. C16027 Page 52of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALAppendix DAcceptable Methods of Contraception
The fo llowing informat ion is based on (and in line with) the informed consent form for ixazo mib.
Female patients: Unless the patient cannot have children because of surgery or other medical 
reasons (had an effect ive tubal ligat ion, had the ovaries or the uterus removed, or is 
postm enopausal), the patient must use 2 effect ive methods of birth control fro m thetime of signing 
the informed consent form through the ent ire study drug treatment period (including interruptions 
in treatment) and for 90 days after completing study drug treatment. It is strongly reco mmended 
that at l east 1 of these 2 methods be highly  effect ive (see examples below).
Highly Effective Methods Other Effective Methods (Barrier Methods)
Intrauterine devices Latex or nonlatex condom with or without a 
spermicidal agent
Hormonal (birth control pills/oral contraceptives, 
injectable contracepti ves, contraceptive patches, or 
contraceptive implants)Diaphragm with spermicide; cervical cap with a 
spermicide; sponge with a spermicide
If one of the highly effective methods cannot be used, using 2 effective methods at the same time is 
recommended.
The patient must use birth control methods as directed above, unless the patient completely avo ids 
having heterosexual intercourse.
Male patients: We do not know if using ixazo mib will affect sperm. Therefore, because o f 
potenti al risk, the pati ent shoul d not get a partner pregnant during the study drug treatment period 
(including interruptions in treatment). Even if the patient is surgically sterilized (ie, had a 
vasectomy ), the pati ent m ust agree to use an appropriate method of barrier contraception (late x or 
nonlatex condo m with or wi thout a spermicidal agent) during the ent ire study  drug treatm ent 
period and for 90 days after completing study  drug treatment, or the pati ent shoul d com pletely 
avoid having heterosexual intercourse.
Highly Effective Methods Other Effective Methods (Barrier Methods)
Vasectomy Latex or nonlatex condom with or without a spermicidal agent
Diaphragm with spermicide; cervical cap with spermicide; sponge with 
spermicide
If one of the highly effective methods cannot be used, using 2 effective methods at the same time is 
recommended.
All patients (male or female) : If the pati ent or a partner becomes pregnant during this study , the 
patient m ust tell the study  doctor immediately. The doctor will advise the patient of the possib le 
risks to the unborn child and discuss options for managing the pregnancy  with the pati ent. For 
female patients who become pregnant while on this study , the study  drug will  be stopped 
immediately , and the pregnancy will be followed unt il conclusio n.
For non-commercial use only
Ixazomib
Study No. C16027 Page 53of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALAppe ndix EDetailed Description of Amendments to Text
The primary sect ion(s) of the protocol affected by the changes in Amendment No. 03 are indicated. 
The corresponding text has been revised throughout the protocol. 
Change 1:Updated the legal ent ity of the sponsor.
The primary change occurs on the cover page, in the Sponsor row: 
Initial 
wording:Millennium Pharmaceuticals, Inc, a who lly owned subsidiary o f Takeda 
Pharmaceut ical Co mpany Limited
40 Landsdowne Street
Cambridge, MA USA 02139
Telephone: +1 (617) 679 -7000
Please note: Millennium Pharmaceut icals, Inc, a who lly owned subsidiary o f Takeda 
Pharmaceut ical Co mpany Limited, may be referred to in this protocol as 
“Millennium,” “Sponsor,” or “Takeda”.
Amended or 
new 
wording:Millennium Pharmaceuticals, Inc, a who lly owned subsidiary of Takeda 
Pharmaceut ical Co mpany Limited Takeda Development Center Americas, Inc
40 Landsdowne Street 95 Hayden Avenue
Cambridge Lexington , MA USA 02139421 USA
Telephone: +1 (617) 679 -7000
Please note: Millennium Pharmaceut icals, Inc, a who lly owned subsidiary o f Takeda 
Pharmaceut ical Co mpany Limited, may be referred to in this protocol as 
“Millennium,” “Sponsor,” or “Takeda”.
Rationale for Change:
To reflect the new legal ent ity for the sponsor of Takeda Development Center Americas rather than 
Millennium. 
For non-commercial use only
Ixazomib
Study No. C16027 Page 54of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALThe fo llowing sect ions also contain this change:
Secti on 2.0STUDY SUMMARY
Secti on 3.2List of Abbreviat ions
Secti on 3.3 Corporate Identificat ion [rem oved]
Secti on 4.1Background
Secti on 6.1Overview of Study  Design
Secti on 6.3.1 Duration of an Individual Pat ient’s Study  Parti cipat ion
Secti on 7.1Inclusion Criteria
Secti on 8.11 Packaging and Labeling
Secti on 8.12 Storage, Handling, and Accountabilit y
Secti on 8.13 Combinat ion Therapy .
Change 2: Updated signatories for the study.
The primary  change occurs in Section 1.2Approval : 
Descript ion 
of change:Removed  and  as 
signatori es.
Added  and  as signatories. 
Rationale for Change:
To reflect the current Takeda personnel responsible for approving the protocol. 
Change 3:Clarified that ixazo mib and/ or combinati onal study  drugs fro m the designated parent 
protocol s will be provided in this study  until other means of accessing treatment are available; no 
new ant icancer agents can be started or added; and for patients whose study therapy in a parent 
study includes placebo, the placebo capsule will be discont inued and crossover to ixazomib is not 
permitted.
The primary  change occurs in Section 6.1Overview of Study  Design : 
Initial 
wording:This is an open -label, mult icenter, rollo ver study  to provi de cont inued access to 
ixazo mib and evaluation o f the long-term safet y profile o f ixazomib. The patient 
popul ation will consist of patients who have previo usly received and tolerated 
ixazo mib in a Millennium -sponsored clinical study, and in the invest igator’s opinio n 
and confirmed by  the Millennium  medical  monitor, m ay benefit fro m continued 
ixazo mib therapy (eg, patient demonstrates response to therapy or stable disease 
without evi dence of disease progression). 
Patients may be enrol led provided they have not met any of the discont inuat ion criteria 
in the parent study . Pati ents will enter this study  on the same ixazomib dose and 
For non-commercial use only
Ixazomib
Study No. C16027 Page 55of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALschedule that they  were receiving in the parent study  (Secti on 8.1). For those patients 
who received ixazo mib dosing based on BSA per the parent study , the dose m ay be 
rounded. The dose may also be rounded for those patients who convert from 
BSA -based dosing to fixed dosing with approval from the Medical Monitor. Patients 
who enter this study  receiving a combin ation therapy  with ixazo mib and another 
medicat ion(s) will continue to receive the combination regimen (which will be 
sourced locally) unt il there is a need to select ively discontinue the other medication(s) 
(eg, due to cumulat ive toxicit y, product expiry, or other factors that limit availabilit y 
from local sources). In that si tuation, the pati ent will  cont inue to receive ixazo mib 
without the di scont inued agent(s), if, in the opinio n of the invest igator and with 
sponsor approval, it is likely that the patie nt will cont inue to derive benefit fro m single 
agent ixazomib; no new anticancer agents can be started or added. Patients receiving a 
combinat ion of ixazo mib and another medicat ion(s) will be discontinued from this 
study  when ixazomib therapy is discont inued.
Following enro llment, patients may receive ixazomib unt il they experience disease 
progression, clinical deterioration in the invest igator’s judgment, experience an 
unacceptable toxicit y, wi thdraw consent, pursue an alternative therapy , meet other 
study -specified reasons for discontinuation of study  drug, or until  ixazo mib is 
available to the patient through commercial channels, including reimbursement for the 
patient’s indicat ion. 
Patients parti cipating in eligible ixazomib parent studies will enter th e rollo ver study  
at the time -point when the rollo ver study  is active at an invest igative site. Following 
their provi sion of informed consent to continue in the rollo ver study , pati ents will  be 
provi ded wi th study  medicat ion. Patients should enter the study within 8 weeks of 
their last dose of ixazomib in the parent study  or as agreed upon by  the Millennium  
clinician/designee.
Amended 
or new 
wording:This is an open -label, mult icenter, rollo ver study  to provi de cont inued access to 
ixazo mib and /or other study drugs from a designated ixazomib parent study (ie, 
Studies C16003, C16005, C16006, C16007, C16008, C16010 Global, C16011, 
C16013, C16014 Global and Korean Continuation, C16017, C16020, C16029, 
and C16047) when the patient has no other means to access study treatment. The 
study will also evaluat ioneof the long-term safet y profile of ixazo mibin those 
patients who continue to receive ixazomib . The pati ent popul ation will  consist of 
patients who have previously  received and tol erated ixazo mibtreatment in a 
Millennium Takeda- sponsored clinical study of ixazomib , and in the investigator’s 
opinio n and confi rmedapproved by the Millennium Takeda medical mo nitor, m ay 
benefit fro m co ntinued ixazo mib therapy  with 1 or more of the drugs from a parent 
protocol (eg, pati ent dem onstrates response to therapy  or stable disease wi thout 
evidence of disease progression). 
Patients may be enrolled provided they have not met any of the discont inuat ion criteria 
in thetheir parent study . Pati ents will enter this study on the same ixazomib dose and,
For non-commercial use only
Ixazomib
Study No. C16027 Page 56of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALschedule of study drug(s), and combination regimen that they  were receiving inat 
the time of rollover from the parent study, or according to the required dose 
modification from a parent study  (Secti on 8.1). For those patients who received 
ixazo mib dosing based on BSA per the parent study, the dose may be rounded. The 
dose m ay also be rounded for those patients who convert from BSA -based dosing to 
fixed dosing with approval fro m the Medical Monitor. Patients who enter this study 
receiving a combinat ion therapy  with ixazomib and another medicat ion(s) will 
continue to receive the combinat ion regimen (which will be sourced locally) until 
there is a need to select ively discont inue the other medicat ion(s) (eg, due to 
cumulative toxicit y, product expi ry, or other factors that limit availabilit y from local 
sources). In that situation, the patient will cont inue to receive ixazo mib wit hout the 
discontinued agent(s), if, in the opinio n of the investigator and with sponsor approval, 
it is likely  that the pati ent will cont inue to derive benefit from single agent ixazo mib; 
noNonew ant icancer agents can be started or added. Patients receiving a combinat ion 
of ixazo mib and another medicat ion(s)Note that for patients whose study therapy 
in a parent study includes a placebo, the placebo capsule will be discontinued from 
this study  when ; crossover to ixazomib therapy  is discontinuedis not permitted .
Following enro llment, patients may receive ixazomib study drug(s) until they 
experience disease progression, clinical deterioration in the invest igator’s judgment, 
experience an unacceptable toxicit y, withdraw consent, pursue an alternat ive therapy, 
meet other study -specified reasons for discont inuat ion of study drug, or until ixazo mib 
is available to the pati ent is transitioned to ixazomib/other therapy through 
commercial channels , including reimbursement for the patient’s indicat ion. 
Patients parti cipat ing in eligible a designated ixazomib parent studies study will ente r 
the rollo ver study  at the time -point when they have completed the EOT visit in the 
parent study and when the rollo ver study is active at an investigative site. Following 
their provi sion of informed consent to continuereceive treatment in the rollo ver 
study, patients will be provided with study medicatio n. Patients should enter the study 
within 8 weeks of their last dose of ixazo mib/other study drug(s) in the parent study 
or as agreed upon by  the Millennium Takeda clinician/designee so to minimize any 
treat ment disruption to the patient .
For non-commercial use only
Ixazomib
Study No. C16027 Page 57of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALRationale for Change:
To clarify the study drug administration and supply language to make provisio n for future patients 
enrolling from designated ixazo mib parent protocols. 
The fo llowing sect ions also contain this change:
Secti on 2.0STUDY SUMMARY
Secti on 4.1.1.2 Benefits .
Secti on 4.2Rationale for the Proposed Study .
Secti on 7.1Inclusion Criteria , Criterion 2.
Secti on 8.1Study  Drug Administrati on. 
Secti on
 8.13 Combinat ion Therapy .
Secti on 9.3Treatment Group Assignments .
Appendix ASchedule o f Events ,
 footnote “l”.
Change 4:Clarified the study  objectives.
The primary  change occurs in Section 5.1.1 Primary Object ives: 
Initial 
wording:The primary  object ive is:
To provi de continued access of ixazo mib and to evaluate the long -term safety  
profile of ixazo mib.
Amended 
or new 
wording:The primary  object ivesisare:
To provide continued access to ixazomib and/or other study drugs from an 
ixazomib parent study.
To provide continued access of ixazo mib and to evaluate the long- term safety  
profile of ixazo mib.
Rationale for Change:
To cl arify that the study  object ives in light of continued access to other study  drugs from  an 
ixazo mib parent study.
The fo llowing sect ions also contain this change:
Secti on 2.0STUDY SUMMARY
Secti on 5.2.1 Primary Endpo int
For non-commercial use only
Ixazomib
Study No. C16027 Page 58of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALChange 5:Clarified the duration of adverse event (AE) fo llow-up.
The primary  change occurs in Section 6.3.1 Duration of an Individual Pat ient’s Study  
Parti cipation: 
Initial 
wording:Patients will be followed for 30 days after the last dose of study drug(s) or the start o f 
subsequent alternative ant icancer therapy . 
Ongo ing AEs meet ing the criteria in Sect ion 10.2 will be fo llowed unt il resolut ion, 
until the AE beco mes chronic or stable, or is determined to be part of the underlying 
disease process, or un til the pat ient starts alternat ive therapy .
Amended 
or new 
wording:Patients will be followed for 30 days after the last dose of study drug(s) or the start o f 
subsequent alternative ant icancer therapy . 
Ongo ing AEs meet ing the criteria in Sect ion 10.2 will be fo llowed unt il resolut ion, 
until the AE beco mes chronic or stable ,or is determined to be part of the underlying 
disease process, or un til the pat ient starts alternat ive therapy attends the EOS visit 
and discontinues the study .
Rationale for Change:
To cl arify that AEs will be fo llowed unt il the pat ient attends an EOS visit and discont inues the 
study; this will occur prior to a patient starting alternat ive therapy. 
The fo llowing sect ions also contain this change:
Secti on 2.0STUDY SUMMARY
Secti on 6.1Overview of Study  Design . 
Secti on 10.3 Moni toring of Adverse Events and Period of Observat ion.
Change 6:Updated the background information on other ixazo mib clinica l trials.
The primary  change occurs in Section 4.1Background : 
Initial 
wording:Ixazo mib is an invest igational, oral , inhibi tor of  the 20S proteasome that is under 
development for the treatment of mult iple myelo ma (MM), plasma cell dyscrasia s, 
amylo idosis, lympho ma, nonhematologic malignancies, and lupus nephrit is. 
Inhibit ion of the 20S proteasome has been validated as a therapeutic target for the 
treatm ent of m alignancies using VELCADE®(bortezomib) for Inject ion, Millennium 
Pharmaceuticals, Inc.’s first -in-class proteasom e inhibi tor [2]. 
Oral ixazomib in co mbinat ion with lenalido mide and dexamethasone was approved 
by the United States (US) Food and Drug Administration (FDA) in November 2015 
for the treatment of patients with MM who have received at least 1 p rior therapy  [
3,4].
…
Phase 1, phase 1/2, and phase 2 trials are ongo ing in MM, relapsed and/or refractory  
For non-commercial use only
Ixazomib
Study No. C16027 Page 59of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALsystemic light -chain amylo idosis (RRAL), so lid tumors, and lympho ma. In addit ion, a 
phase 1 study  is ongoing in pa tients wi th renal  impai rment who have relapsed and/or 
refractory  multiple myel oma (RRMM) or advanced solid tumors (Study  C16015). 
Phase 1 studies have been co mpleted in pat ients with hepat ic impairment who have 
advanced so lid tumors or hematologic malignan cies (Study  C16018) and in an 
absorpti on, di stribut ion, metabo lism, and excret ion study  in pat ients with advanced 
solid tumors or lympho ma (Study  C16016). Phase 3 trials in RRMM, newly 
diagnosed m ultiple myelo ma (NDMM), and RRAL are underway . As of 27 Marc h 
2016, data are available fro m 929patients known to have received at least 1 dose of 
either the intravenous (IV) or oral ixazomib formulations across the clinical 
development program; 2417 patients have been enrolled in 5 phase 3 clinical trials:
Doubl e-blind, placebo -controlled Study  C16010 and Study  C16010 China 
continuat ion study  (CCS) of ixazo mib versus placebo in co mbinat ion with 
lenalido mide + dexamethasone (LenDex) in pat ients wi th RRMM.
Doubl e-blind, placebo -controlled Study  C16014 and Study  C16014 extensio n in 
South Korea (KES) of ixazo mib versus placebo in combinat ion with LenDex in 
patients wi th NDMM. 
Doubl e-blind, placebo -controlled Study  C16019 of ixazo mib versus placebo as 
maintena nce in patients with NDMM who have undergone autologous stem cell 
transpl antati on (ASCT) before entering the study .
Doubl e-blind, placebo -controlled Study  C16021 of ixazo mib versus placebo as 
maintenance in patients with NDMM who have not undergone ASCT.
Open-label Study  C16011 of ixazomib and dexamethasone versus physician’s 
choice o f a dexamethasone -containing regimen in patients with RRAL. 
Ixazo mib is available as an IV and oral formulat ion (during the early  devel opment of  
ixazo mib); however, only the o ral formulation is currently being developed for 
commercializat ion. Regardless of the route of administration, in the twice -weekly  
dosing schedule, ixazo mib is given on Days 1, 4, 8, and 11 of a 21 -day cycle, and in 
the weekly dosing schedule, ixazomib is given on Days 1, 8, and 15 of a 28 -day cycle. 
Schedules with longer cy cles are being invest igated in Study  C16006. 
The fo llowing oncology  indicat ions are being studied during the clinical development 
of ixazo mib: RRMM, NDMM, RRAL, advanced solid tumors, a nd advanced 
lympho ma. Studies are investigating both single -agent ixazo mib and ixazo mib in 
combinat ion with standard treatments. However, other therapeutic areas are also being 
explored.
Amended 
or new 
wording:Ixazo mib is an invest igational, oral , inhibi tor of  the 20S proteasome that is under 
development has been studied for the treatment of mult iple myelo ma (MM), pl asma 
cell dyscrasias, amylo idosis, lymphoma, nonhematologic malignancies, and lupus 
nephrit is. Inhibit ion of the 20S proteasome has been validated as a therapeutic target 
For non-commercial use only
Ixazomib
Study No. C16027 Page 60 of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALfor the treatment of malignancies using VELCADE®(bortezomib) for Injection, 
Millennium TakedaPharmaceuticals, Inc.’s first-in-class proteasome inhibitor [2]. 
Oral ixazomib in combination with lenalidomide and dexamethasone was first 
approved by the United States (US) Food and Drug Administration (FDA)in 
November 2015 for the treatment of patients with MM who have received at least 1 
prior therapy [3,4].It has since been approved in over 65 countries globally.
…
Phase 1, phase1/2, and phase 2 trials are ongoing have been conducted in MM, 
relapsed and/or refractory systemic light-chain amyloidosis (RRAL), solid tumors, 
and lymphoma. In addition, a phase 1 study is ongoing studies were conducted in 
patients with renal impairment who have hadrelapsed and/or refractory multiple 
myeloma (RRMM) or advanced solid tumors (Study C16015). Phase 1 studies have 
been completed ,in patients with hepatic impairment who have hadadvanced solid 
tumors or hematologic malignancies (Study C16018) ,and in an absorption, 
distribution, metabolism, and excretion study in patients with advanced solid tumors 
or lymphoma (Study C16016). Phase3 trials in RRMM (C16010), newly diagnosed 
multiple myeloma (NDMM) (C16014), and RRAL are underway. As of 27 March 
2016, data are available from 929patientsknown to have received at least 1 dose of 
either the intravenous (IV) or oral ixazomib formulations across the clinical 
development program; 2417 patients have been enrolled in 5phase3 clinical trials:
(C16011) have additionally been completed. Phase 3 trials of ixazomib 
Doubleblind, placebocontrolled Study C16010 and Study C16010 China 
continuation study (CCS) of ixazomib versus placebo in combination with
lenalidomide + dexamethasone (LenDex) in patients with RRMM.
Doubleblind, placebocontrolled Study C16014 and Study C16014 extension in 
South Korea (KES) of ixazomib versus placebo in combination with LenDex in 
patients with NDMM. 
Doubleblind, placebocontrolled Study C16019 of ixazomib versus placebo as 
maintenance in patients with NDMM who have undergone maintenance therapy 
followingautologous stem cell transplantati on (ASCT) before entering the 
study C16019) or in patients who did not receive ASCT (C16021) are ongoing .
Doubleblind, placebocontrolled Study C16021 of ixazomib versus placebo as 
maintenance in patients with NDMM who have not undergone ASCT.
Openlabel Study C16011 of ixazomib and dexamethasone versus physician’s 
choice of a de xamethasonecontaining regimen in patients with RRAL. 
Ixazomib is had beenavailable as an IVand oral formulation (during the early 
development of ixazomib); however, only the oral formulation is currently being 
developed for commercialization. Regardless of the route of administration, in the 
twice-weekly dosing schedule, ixazomib is given on Days 1, 4, 8, and 11 of a 21-dayFllacFor ndyon-commercial use onlyC1
nt whot who
6018)18),an
y in patiein pa
als in RRs in R
, and RRand R
atientsentsknkrcl ixazomixazommeatients htientsmmnally belly b
boocontrcon(CCS(CCy(CCS)(CCyno+ dexam+ dexamorplplaceaF
Ixazomib
Study No. C16027 Page 61of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALcycle, and in the weekly dosing schedule, ixazo mib is given on Days 1, 8, and 15 of a 
28-day cycle. Schedules wit h longer cycles are being invest igated in Study  C16006. 
The fo llowing oncol ogy indicat ions are beinghave been studied during the clinical 
development of ixazomib: RRMM, NDMM, RRAL, advanced solid tumors, and 
advanced lympho ma, and pediatric acute lymphoblastic leukemia . Studies are 
investigat ing both single -agent ixazo mib and ixazomib in co mbinat ion with standard 
treatments. However, other therapeutic areas are also being explored.
Rationale for Change:
To update the current status of the ixazo mib development program.
Change 7:Clarified the ant icipated number of patients and sites/countries.
The primary  change occurs in Section 6.2Number of Patients : 
Initial 
wording:The maximum number of pat ients to be enrolled is estimated to be 250 .The number of 
countri es and sites cannot be determined as this study is open to all countries and sites 
with qualifying patients from prior company -sponsored ixazomib studies.
Amended 
or new 
wording:The maximum estimated number of pat ients to be enro lled is estimated to 
beapproximately 250.The number of countries and sites cannot be determined is not 
currently specified as thi s study  is open to all countries and sites with qualifying 
patients f rom prior com pany -sponsored ixazo mib studies.
Rationale for Change:
To provi de clarificat ion. 
Secti on 2.0STUDY SUMMARY also contains this change. 
Change 8:Clarified the duration of an individual patient’s study participat ion.
The primary  change occurs in Section 6.3.1 Duration of an Individual Pat ient’s Study  
Parti cipation: 
Initial 
wording:The ant icipated durati on of  treatm ent in this rollo ver study  will be up to 5 years.
Patients will  be followed for 30 days after the last dose of ixazomib or the start of 
subsequent alternative ant icancer therapy . 
For non-commercial use only
Ixazomib
Study No. C16027 Page 62of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALAmended 
or new 
wording:The ant icipated durati on of  treatm ent for an individual patient in this rollo ver study  
will be up to 5 years. approximately 5 years. Based on approval by the Takeda 
medical monitor every 24 months, c ontinued access to ixazomib and/or other 
study drugs will be allowed for patients who in the investigator’s opinion are 
deriving clinical benefit. Patients may remain in the rollover study until they are 
transitioned to ixazomib/other therapy through commercial channels or until 
any of the other reasons for treatment discontinuation are met, whichever is 
sooner.
Patients will  be followed for 30 days after the last dose of ixazomib study drug(s) or 
the start of subsequent alternat ive anticancer therapy , whichever occurs earlier . 
Rationale for Change:
To provi de clarificat ion. 
The fo llowing sect ions also contain this change:
Secti on 2.0STUDY SUMMARY . 
Secti on 6.3.3 Timeframe for Primary  Endpo int to Support Disclo sures .
Change 9:Clarified the ant icipated total  study  durati on.
The primary  change occurs in Section 6.3.2 End of Study /Study  Com pletion Definit ion and 
Planned Reporting : 
Added text: The est imated time frame for study co mpletion (first patient in to last patient last visit) 
isapproximately 7years.
Rationale for Change:
To add flexibilit y to the anti cipated total  study  durati on. 
The fo llowing sect ions also contain this change:
Secti on 2.0STUDY SUMMARY . 
Secti on 6.3.3 Timeframe for Primary  Endpo int to Support Disclo sures .
Secti on6.3.4 Total Study  Durati on.
Change 10:Specified the acceptable methods of contraception to preven t pregnancy.
The primary  change occurs in Section 7.1Inclusio n Cri teriaand Appendix D: 
Descript ion 
of change:Added Appendix Dto describe acceptable methods of contracep tion.
Added a referenced to Appendix Din Section 7.1, Inclusio n Cri terion 3.
For non-commercial use only
Ixazomib
Study No. C16027 Page 63of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALRationale for Change:
To incorporate the acceptable methods of contraception appendix (first added to Sweden -specific 
Protocol  Amendment 02) into the Global protocol. 
Change 11:Clarified that systemic treatment with strong cytochrome P -450 (CYP)3A inducers is 
prohibited for patients receiving ixazomib during the study .
The primary  change occurs in Section 8.4Excluded Concomitant Medicat ions and Procedures : 
Initial 
wording:Systemic treatm ent wi th strong CYP3A inducers (rifampin, rifapent ine, rifabut in, 
carbamazepine, phenyto in, phenobarbital), or use of St. John’s wort.
Amended 
or new 
wording:For patients receiving ixazomib, s Systemic treatment with strong CYP3A 
inducers (rifampin, rifapent ine, rifabutin, carbamazepine, phenytoin, 
phenobarbital), or use of St. John’s wort.
Rationale for Change:
To add cl arity to this protocol . 
The following sect ions also contain this change:
Secti on 2.0STUDY SUMMARY . 
Secti on 6.1Overview of Study  Design .
Change 12:Updated the management of ixazo mib clinical events to align with the current 
program standards.
The primary  change occurs in Section 8.7.1 Management of Ixazo mib Clinical Events : 
Initial 
wording:Prophylaxis Against Risk of Reactivation of Herpes Infection
Patients may be at an increased risk of infect ion, incl uding reactivation of herpes 
zoster and herpes simplex viruses. Ant iviral therapy , such as acycl ovir, valacycl ovir, 
or other antivirals, may be init iated as clinically indicated. 
Nausea or Vomiting
Standard anti -emet ics, including serotonin 5 -hydroxy tryptamine 3 receptor 
antagonists, are recommended for emesis if it occurs; prophylact ic ant i-emet ics may 
also be considered at the physician’s discretion. Fluid deficit should be corrected 
during treatme nt.
Diarrhea
Diarrhea shoul d be managed according to clinical practice, including the 
administration of antidiarrheals once infect ious causes are excluded. Fluid intake 
shoul d be maintained to avoi d dehydrat ion. Fluid deficit should be corrected during 
treatment.
For non-commercial use only
Ixazomib
Study No. C16027 Page 64of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALErythematous Rash With or Without Pruritus
Rash may  range from  limited ery thematous areas, macular or small papular bumps 
that may  or m ay not be pruri tic over a few areas of the body , to a m ore generalized 
eruption that i s predominant ly on the trunk or extremit ies. Rash has been most 
commo nly characterized as maculopapular or macular. To date, when it does occur, 
rash is most comm only reported wi thin the first 3 cycles of therapy . The rash is often 
transi ent and self -limit ing and is ty pically Grade 1 or 2 in severit y. If rash occurs, 
consideration should be given to alternate causes of the rash such as conco mitant 
medicat ions, infect ions, etc.
Symptom atic measures such as antihistamines or corticosteroids (oral or topical) have 
been successfully used to manage rash and have been used prophylactically  in 
subsequent cycles. The use of a topical, IV, or oral steroid (eg, pr ednisone ≤ 10 mg per 
day or equivalent is permitted. Management of a Grade 3 rash may  require IV 
antihistamines or corticosteroids. Administration of ixazo mib (and other causative 
agent if given in co mbinat ion) should be modified and re -initiated at a redu ced level 
from where rash was noted (per parent study ).
In line with clinical practice, dermatology  consul t and bi opsy of Grade 3 or hi gher 
rash or any  SAE invo lving rash is recommended. Prophylact ic measures should also 
be considered if a patient has prev iously developed a rash (eg, using a thick, 
alcoho l-free emo llient cream on dry  areas of the body  or oral  or topi cal 
antihistamines). 
The rare risks of Stevens -Johnson syndro me, toxic epidermal necro lysis (TEN), drug 
reacti on wi th eosinophilia and systemi c symptom s (DRESS syndrom e), and 
pemphigus vulgaris have been reported in oncology  studi es when ixazo mib (or 
placebo) was given with conco mitant m edicati ons that are known to cause rash (eg, 
Bactrim, lenalido mide, aspirin), and/or in the setting of confoun ding 
treatm ent-emergent AEs. These severe, poten tially life -threatening or deadly  
condi tions may  involve rash with skin peeling and mouth sores and should be 
clinically managed according to standard medical practice. Punch biopsies for 
histopathological analysis are encouraged at the discretion of the invest igator. 
Addit ional information regarding these reactions can be found in the IB.
Thrombocytopenia
Blood counts shoul d be m onitored regul arly according to standard clinical pract ice. 
Thrombocy topeni a may  be severe but has been manageable with platelet transfusio ns 
according to standard clinical pract ice. Ixazo mib administration should be modified 
according to dose modificat ion recommendat ions in the parent study  when 
thrombocy topenia occurs. Therapy  can be reinit iated at a reduced level upon recover y 
of platelet counts. A rare ri sk is thromboti c thrombocy topeni c purpura, a rare blood 
disorder where blood clots form in small blood vessels throughout the body  
characterized by  thrombocy topeni a, petechiae, feve r, or possibly  more seri ous signs 
For non-commercial use only
Ixazomib
Study No. C16027 Page 65of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALand symptoms. Thrombotic thrombocy topeni c purpura shoul d be managed 
symptom atically according to standard medical practice.
…
Fluid Deficit
Dehydrat ion shoul d be avo ided because ixazomib may cause vo miting, di arrhea, and 
dehydrat ion. Acute renal failure has been reported in patients treated with ixazomib, 
commo nly in the setting of the previously  noted gastrointestinal toxicit ies and 
dehydrat ion.
Fluid deficit should be corrected before administration of study  drug and as n eeded 
during treatment to avoid dehydrat ion.
…
Posterior Reversible Encephalopathy Syndrome
Posterior reversible encephalopathy syndrome, which ult imately reso lved, has been 
reported with ixazo mib. This condit ion is characterized by headache, seizures, and
visual loss, and abrupt increase in blood pressure. Diagnosis may be confirmed by 
magnet ic resonance imaging or computed tomography. If the syndrome is diagnosed 
or suspected, symptom -directed treatm ent shoul d be m aintained unt il the condit ion is 
reversed by control of hypertensio n or other inst igating factors.
Transverse Myelitis
One case of transverse myelit is has been reported with ixazo mib. It is not known 
whether ixazo mib causes transverse myelit is; however, because transverse myelit is 
happened to a p atient receiving ixazo mib, the possibilit y that ixazomib may  have 
contributed to the transverse myelitis cannot be excluded. Transverse myelit is should 
be managed according to standard medical pract ice.
Overdose
An overdose is defined as a known deliberate or accidental administration of 
investigat ional drug, to or by a study subject, at a dose above that which is assigned to 
that individual subject according to the study  protocol . If overdose occurs, consider 
close observati on including hospitalizat ion forhemo dynamic support. Gastric lavage 
may be considered if inst ituted wi thin 1 hour of ingestion of ixazo mib overdose.
…
Amended 
or new 
wording:Prophylaxis Against Risk of Reactivation of Herpes Infection
Patients m ay be at an increased risk of infect ion, incl uding reactivation of herpes 
zoster and herpes simplex viruses. All patients continuing to receive ixazomib in 
this rollover study should receive prophylactic Aantiviral therapy , such as 
acyclovir, valacyc lovir, or other antivirals, may be init iated as . Patients receiving a 
non-ixazomib -containing regimen should be guided by the physician's clinical ly
For non-commercial use only
Ixazomib
Study No. C16027 Page 66of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALindicated practice .
Nausea or Vomiting
Prophylaxis with Sstandard anti emeti cs, including serotonin 5- hydroxy tryptamine 3 
receptor antagonists, areisrecommended for emesis if it occurs; prophylact ic 
antiemet ics may also be considered at the physician’s discret ion.. Any Ffluid deficit 
shoul d be corrected occurring during treatment should be promptly corre cted. 
Diarrhea
Diarrhea shoul d be managed according to clinical practice, including the 
administration of antidiarrheals once infect ious causes are excluded. Fluid intake 
shoul d be maintained to avoi d dehydrat ion. Any Ffluid deficit shoul d be 
corrected occurring during treatment should be promptly corrected .
Erythematous Rash With or Without Pruritus
Rash may  range from  limited ery thematous areas, macular or small papular bumps 
that may  or m ay not be pruri tic over a few areas of the body , to a m ore generali zed 
eruption that i s predominant ly on the trunk or extremit ies. Rash has been most 
commo nly characterized as maculopapular or macular. To date, when it does occur, 
rash is most commonly reported within the first 3 cycles of therapy . The rash is often 
trans ient and self -limit ing and is ty pically Grade 1 or 2 in severit y. If rash occurs, 
consideration should be given to alternate causes of the rash such as conco mitant 
medicat ions, infect ions, etc ; these other causative agents should be discontinued 
and altera tive agents considered if medically necessary .
Symptom atic measures such as antihistamines or corticosteroids (oral or topical) have 
been successfully used to manage rash and have been used prophylactically  in 
subsequent cycles. The use of a topical, IV, or oral steroid (eg, prednisone ≤ 10 mg per 
day or equivalent )is permitted. 
Management of a Grade 3 rash may require IV ant ihistamines or corticosteroids. 
Administrati on of ixazo mib (and other causative agent if given in combinat ion) should 
be modified and re -initiated at a reduced level from where rash was noted (per parent 
study ). In line wi th clinical practice, dermatology  consul t and bi opsy  of Grade 3 or 
higher rash or any SAE invo lving rash is recommended. Prophylactic measures should 
also be consid ered if a patient has previously developed a rash (eg, using a thick, 
alcoho l-free emo llient cream on dry  areas of the body  or oral  or topi cal 
antihistamines). 
The rare risks of Stevens -Johnson syndro me, toxic epidermal necro lysis (TEN), drug 
reacti on wi th eosinophilia and systemic symptoms (DRESS syndro me), and 
pemphigus vulgaris have been reported in oncology  studi es when ixazo mib (or 
placebo) was given with conco mitant m edicati ons that are known to cause rash (eg, 
Bactrim, lenalido mide, aspirin), and/or in the setting of confounding 
treatm ent-emergent AEs. These severe, poten tially life -threatening or deadly  
For non-commercial use only
Ixazomib
Study No. C16027 Page 67of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALcondi tions may  involve rash with skin peeling and mouth sores and should be 
clinically managed according to standard medical practice. Punch biopsie s for 
histopathological analysis are encouraged at the discretion of the invest igator. Study 
medications should be discontinued in the event of severe, potentially 
life-threatening rash. Addit ional informat ion regarding these reactions can be found 
in the IB.
Thrombocytopenia
Blood counts shoul d be m onitored regul arly according to standard clinical pract ice. 
Thrombocy topeni a may  be severe but has been manageable with platelet transfusio ns 
according to standard clinical pract ice. Ixazo mib administration shou ld be modified 
according to dose modificat ion recommendat ions in the parent study  when 
thrombocy topenia occurs. Therapy  can be reinit iated at a reduced level upon recover y 
of platelet counts. A rare risk is Thrombotic microangiopathy (TMA), including
thrombotic thrombocy topeni capurpura , aand hemolytic uremic syndrome, are
rare, serious blood disorder swhere that cause low levels of platelets and red blood 
cells and result in blood clots form in small blood vessels throughout the body  
characterized by  thromb ocytopeni a, petechiae, fever, or possibly  more seri ous signs 
and symptoms. Thrombotic thrombocy topeni c purpura shoul d be managed 
symptom atically . Symptoms may include fatigue, fever, bruising, nose bleeds, and 
decreased urination. These disorders, including fatal cases, have been reported 
in patients receiving ixazomib. If TMA is suspected, consider withdrawal of the 
suspected causative agent and manage according to standard medical pract ice.
…
Fluid Deficit
Dehydrat ion shoul d be avo ided because ixazomib ma y cause vo miting, di arrhea, and 
dehydrat ion. Acute renal failure has been reported in patients treated with ixazomib, 
commo nly in the setting of the previously  noted gastrointestinal toxicit ies and 
dehydrat ion.
Fluid deficit should be promptly corrected before administration of study drug and as 
needed during treatment to avoid dehydrat ion.
…
Posterior Reversible Encephalopathy Syndrome
Posterior reversible encephalopathy syndrome, which ult imately reso lved, has been 
reported with ixazo mib. This condit ionis usually transient and reversible. It is 
characterized by  headache, seizures, and visual loss, and abrupt increase in blood 
pressure. Di agnosis m ay be confirmed by magnet ic resonance imaging or computed 
tomography . If the syndro me is diagnosed or suspec ted, symptom -directed treatm ent 
shoul d be maintained unt il the condit ion is reversed by control of hypertension or 
other instigating factors.
For non-commercial use only
Ixazomib
Study No. C16027 Page 68of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALTransverse Myelitis
One case of t Transverse myelit is has been reported with ixazo mib. It is not known 
whether ixazo mib causes transverse myelit is; however, because transverse myelit is 
happened to a patient receiving ixazo mib, the possibilit y that ixazomib may  have 
contributed to the transverse myel itis cannot be excluded. Transverse myelit is should 
be managed according to standard medical pract ice.
Overdose
An overdose is defined as a known deliberate or accidental administration of 
investigat ional drug, to or by a study subject, at a dose above tha t which is assigned to 
that individual subject according to the study  protocol . Overdose has been reported 
in patients taking ixazomib. Symptoms of overdose are generally consistent with 
the known risks of ixazomib. Reports of accidental overdose have been
associated with serious adverse events, such as nausea, lung infections including 
aspiration pneumonia, multiple organ failure, and death. If overdose occurs, 
consider close observation including hospitalization for hemodynamic support. 
Gastri c lavage may be considered if inst ituted wi thin 1 hour of ingestion of ixazo mib 
overdose.
…
Rationale for Change:
To add informat ion current ly available around clinical events.
Change 13:Clarified the instructions for management of co mbinat ion therapy  clinical  events.
The primary  change occurs in Section 8.7.2 Management of Combinat ion Therapy Clinical 
Events : 
Initial 
wording:For each medicat ion(s) used as combinat ion therapy wit h ixazo mib please refer to the 
prescribing information for the applicable medication used in combinat ion with 
ixazo mibfor the m anagement of the clinical events.
Amended 
or new 
wording:For each medicat ion(s) used as combinat ion therapy wit h or without ixazo mib,please 
refer to the prescribing informat ion and details in the parent protocol for the 
applicable medicat ion used in combinat ion with ixazomib for the management of the 
clinical events. 
Rationale for Change:
To add cl arificat ion to thi s protocol . 
Change 14:Updated the storage, handling, and accountabilit y text to cl arify  procedures and 
account for the COVID -19 pandemic.
The primary  change occurs in Section 8.12 Storage, Handling, and Accountabilit y: 
For non-commercial use only
Ixazomib
Study No. C16027 Page 69of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALInitial 
wording:On receipt at the invest igative site, ixazo mib should remain in the blister and carton 
provi ded unt il use or dispensat ion. The container should be stored as directed by  the 
label on the packaging. All excursio ns should be brought to the sponsor’s attention for 
assessment and authorizat ion for continued use. Ensure that the drug is used before the 
retest expiry  date provi ded by  Millennium . Expiry  extensi ons will be co mmu nicated 
accordingly with updated documentation to support the extend ed shelf life.
Ixazo mib dispensed to the patient for take -home dosing should remain in the blister 
packaging and carton and stored as directed by the label on the packaging as noted 
previously until the point of use. Patients who are receiving take -home medicati on 
shoul d be given a supply of study  drug as per the parent study  schedule or for up to 
3cycles at the di screti on of  the invest igator. Com prehensive instructions should be 
provi ded to the patient to ensure compliance wit h dosing procedures and to av oid the 
potenti al for incorrect self -administrati on or overdose of medication. Patients should 
be instructed to store the medicat ion as directed by the label on the packaging. Patients 
shoul d be instructed to return their empt y or partially used cartons to the invest igative 
site at their next visi t, rather than discarding them, as permitted by  site policy . 
Reconciliat ion will occur accordingly when the patient returns at their next visit for 
take-home medicat ion. Any excursio ns in temperature should be repo rted and dealt 
with on a case -by-case basis. 
Amended 
or new 
wording:On receipt at the invest igative site, ixazo mib should remain in the blister pack and 
carton provided until use or dispensat ion. The container should be stored as directed 
by the l abel o n the packaging. All excursio ns should immediately be brought to the 
sponsor’s attention for assessment and authorizat ion for continued use. Ensure that the 
drug i s used before the retest expiry  date provi ded by  Millennium Takeda. Expi ry 
extensio ns will be communicated accordingly wit h updated documentation to support 
the extended shelf life.
Ixazo mib dispensed to the patient for take -home dosing should remain in the blister 
packaging and carton and stored as directed by the label on the packaging as noted 
previously until the point of use. Patients who are receiving take -home medication 
shoul d be given a supply of study  drug as per the parent study  schedule or for up to 
3cycles at the di screti on of  the invest igator. (Note: Patients in France are only 
permit ted to receive 1 cycle of medication at a time). In case of the COVID -19 
pandemic preventing a patient from attending the study site, sites may use 
alternative strategies to deliver study drug to patients (eg, via courier or site 
staff), per local standard practice and regulations and with prior approval from 
the investigator and the sponsor’s project clinician/designee. Comprehensive 
instructi ons shoul d be provi ded to the pati ent to ensure compliance wi th, and 
understanding of, dosing procedures and to avo id the potential for incorrect 
self-administrati on or overdose of medication. 
Patients shoul d be instructed to store the medicat ion as directed by  the l abel on the 
packaging. Patients should be instructed to return their empt y or partially used cartons 
For non-commercial use only
Ixazomib
Study No. C16027 Page 70of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALtothe invest igative site at their next visit, rather than discarding them, as permitted by 
site policy. Reconciliat ion will occur accordingly when the patient returns at their next  
visit for take -home medicat ion. In case of the COVID- 19 pandemic preventing a 
patient from attending the study site, drug packs and dosing diaries should be 
returned at the next available on -site clinic visit. Any excursio ns in temperature 
shoul d be reported and deal t with on a case -by-case basis. 
Rationale for Change:
To add clarificat ion to thi s protocol .
Change 15:Added language regarding alternat ive methods for administe ring study  
procedures/assessments when it is not possible for the patient to come to the study  site due to the 
COVID -19 pandemic.
The primary  change occurs in Section 9.4Study  Procedures : 
Added text: In acknowledgement of hospital, local, state or national government restrictions, 
or other site- related factors caused by the COVID -19 pandemic that may 
prevent investigators from conducting the study according to the Schedule of 
Events at the clinical study site, investigators may conti nue patients in the study 
despite departure from the Schedule of Events. Investigators are expected to 
evaluate the impact to the safety of the study participants and site personnel for 
patients to continue. In evaluating such requests, the investigator/st udy site staff 
will give the highest priority to the safety and welfare of the patients. Patients 
must be willing and able to continue taking study medication and remain 
compliant with the protocol. For patients that are impacted by the COVID -19 
pandemic, any procedures not conducted per the study protocol will be 
documented in the eCRF. 
Alternative methods should be considered for performing the assessments by 
other means than the patient presenting to the clinic (eg, remote assessment, 
having lab assessment performed at a facility closer to the patient’s home, etc.) If 
a patient misses an in -person study visit, the investigator/study team staff will 
speak directly with the patient by telephone or other medium (eg, a 
computer -based video communicati on) during each visit window to assess 
subject safety and overall clinical status. During this contact with the patient, the 
study site physician or other qualified site staff should at minimum conduct AE 
collection and an assessment of clinical symptoms. Other study assessments may 
be collected remotely as is feasible and may involve audio or video recording. 
Assessments/procedures that cannot be completed during the protocol -specified 
window because a site visit is done remotely (eg, hematology, clinical chemistry, 
concomitant medications/procedures) are waived. 
For non-commercial use only
Ixazomib
Study No. C16027 Page 71of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALRationale for Change:
To accoun t for the COVID -19 pandemic affect ing study  conduct.
Change 16:Clarified that patients previously enro lled in this study who remain on study treatment 
upon implementation of Amendment 3 may need to be reconsented, according to IRB/IEC 
standards.
The primary  change occurs in Section 9.4.1 Informed Consent : 
Added text: Patients previously enrolled in this study who remain on study treatment upon 
implementation of Amendment 3 may need to be reconsented, according to 
IRB/IEC standards. Reconsenting should be done in person, where possible. 
Remote reconsenting is permitted as long as the process adheres to site, 
IRB/IEC, and G CP standards and local regulations.
Rationale for Change:
To clarify that patients previously enro lled and still on treatment in this rollo ver study may need to 
reconsent.
The fo llowing sect ions also contain this change:
Secti on 15.2 Subject Informat ion, Informed Consent, and Subject Authorizat ion. 
Appendix ASchedule o f Events, footnote “d”.
Change 17:Clarified regional exceptions for assessment of carbon dioxide, depending on 
standard of care.
The primary  change occurs in Section 9.4.8.1 Clinical Chemistry, Hematology, and Urinalysis : 
Descript ion 
of change:Footnote adde d to “Carbon Dioxide” in Table 9.a Clinical Chemistry  and 
Hem atology Tests .
Added text:aIf CO 2is not done as a part of standard care in the participant’s region, then 
this test does not need to be performed.
Rationale for Change:
To cl arify assessments in this protocol.
Change 18:Updated the criteria for withdrawing patients from study.
The primary  change occurs in Section 9.6Withdrawal  of Patients From  Study : 
Initial 
wording:A pat ient will be withdrawn fro m the study  for any of the fo llowing reasons:
Study  terminated by  sponsor.
Withdrawal by subject.
For non-commercial use only
Ixazomib
Study No. C16027 Page 72of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALLost to follow -up. 
Death.
A pat ient may also be wi thdrawn from  the study  for any  of the f ollowing reasons:
Adverse event.
Protocol  deviat ion. 
Progressive disease (as defined in the pat ient’s parent study ). 
Clinical deterioration, in the investigator’s opinio n. 
Pregnancy.
Other.
Amended 
or new 
wording:A pat ient will be withdrawn fro m the study  for any of the following reasons:
Progressive disease (as defined in the patient’s parent study). 
Pregnancy.
Transition to commercial supply of study drug(s).
Study  terminated by  sponsor.
Withdrawal by subject.
Lost to follow -up.
Death.
A pat ient may also be wi thdrawn f rom the study  for any  of the f ollowing reasons:
Adverse event.
Protocol  deviat ion. 
Progressive disease (as defined in the pat ient’s parent study ). 
Clinical deterioration, in the investigator’s opinio n.
Pregnancy Investigator’s decision .
Other.
Rationale for Change:
To cl arify the wi thdrawal  criteria in this protocol . 
For non-commercial use only
Ixazomib
Study No. C16027 Page 73of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALChange 19:Added language to Procedures for Recording an d Reporting Adverse Events and 
Serious Adverse Events.
The primary  change occurs in Section 10.2 Procedures for Recording and Reporting Advers e 
Events and Serious Adverse Events : 
Added text: The paper SAE forms must be submitted via fax (see fax numbers below) within 
24 hours of awareness. In case of fax, site personnel must confirm successful 
transmission of all pages and include an e -mail address on the fax cover sheet so 
that an acknowledgment of receipt can be return ed via e -mail within 1 business 
day. E -mail submission of paper SAE forms with a PDF attachment should only 
be used in the case where fax is not possible within 24 hours of receiving the 
event. In case of e -mail, site personnel must confirm successful tran smission by 
awaiting an acknowledgment of the receipt via e- mail within 1 business day. If 
SAEs are reported via fax or by e -mail, the EDC application must be updated as 
soon as possible with the appropriate information.
Rationale for Change:
To assi st in timely  submissi on of  SAE reports.
Change 20:Revised language regarding the statistical analyses.
The primary  change occurs in Section 13.1.3 Safety Analysis : 
Initial 
wording:The fo llowing AEs will be summarized using the FAS: 
All SAEs.
All ≥Grade 3 AEs. 
≥Grade 2 peripheral neuropathy .
New primary malignancies. 
Any AE result ing in dose modificat ion or discont inuat ion of any  study  drug.
Any other AE that in the opinio n of the invest igator is a clinically significant 
event. 
No stati stical testing or inferent ial statistics will be generated.
All AEs will be coded using MedDRA. Data will be summarized using preferred term 
and primary system organ class. Local laboratory  assessme nt changes and vital sign 
changes fro m study  entry  to end of study  will also be summarized.
Exposure to study  drug and study  regimen will be tabulated. In addition, reasons for 
drug di scontinuati on will  be summarized. 
Concomitant medicat ions and procedure s related to treatment of AEs fro m screening 
through the end of study  will be cl assified by generi c term s according to the WHO 
For non-commercial use only
Ixazomib
Study No. C16027 Page 74of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALdrug di ctionary. 
Data will be presented by the ent ire safet y popul ation, by  populati on of  monotherapy  
of ixazo mib and by populat ion of ixazomib in co mbinat ion with other anti cancer 
agents(s) as specified in the SAP. Addit ional safety  analyses by subgroups such as 
drug indicat ion and baseline characterist ics may be performed as specified in the SAP. 
Amended 
or new 
wording:The fo llowing AEs will be summarized with descriptive statistics for all patients 
who receive at least 1 dose of ixazomib using the FAS: 
All SAEs.
All ≥Grade 3 AEs. 
≥Grade 2 peripheral neuropathy .
New primary malignancies. 
Any AE result ing in dose modif ication or discont inuat ion of any  study  drug.
Any other AE that in the opinio n of the invest igator is a clinically significant 
event. 
No formal statistical testing or inferent ial stati stics will be generated.
All AEs will be coded using the current MedDRA version at the time of the 
analysis . Data will be summarized using preferred term and primary  system  organ 
class. Local laboratory  assessment changes and vital sign changes fro m study  entry  to 
end of study  will also be summarized.
Exposure to study  drug a nd study  regimen will be tabulated. In addition, reasons for 
drug di scontinuati on will  be summarized. 
Concomitant medicat ions and procedures related to treatment of AEs fro m screening 
through the end of study  will be cl assified by generi c term s according to the WHO 
drug di ctionary. 
Data will be presented by the ent ire ixazomib safety  popul ation, by popul ation of 
monotherapy  of ixazo mib,and by population o f ixazomib in co mbinat ion with other 
anticancer agents(s) as specified in the SAP. Safety listings wi ll be prepared for 
patients receiving other study drugs and not ixazomib. Addit ional safet y analyses 
by subgroups such as drug indicat ion and baseline characterist ics may be per formed as 
specified in the SAP.
Rationale for Change:
To cl arify the stati stical analyses for this study . 
Secti on 2.0STUDY SUMMARY also contains this change.
Change 21:Clarified language regarding procedures for reporting product complaints or 
For non-commercial use only
Ixazomib
Study No. C16027 Page 75of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALmedicat ion errors.
The change occurs in Sect ion 10.5 Procedures for Reporting Product Complaints or Medi cation 
Errors (Including Overdose) : 
Initial 
wording:A product complaint is a verbal, written, or electronic expression that implies 
dissatisfaction regarding the ident ity, strength, puri ty, quali ty, or s tabilit y of a drug 
product. Individuals who ident ify a potential product complaint s ituation shoul d 
immediately  report thi s via the phone numbers or e -mail addresses provided below.
A medicat ion error is a preventable event that involves an ident ifiable pat ient and that 
leads to i nappropri ate medicat ion use, which may  resul t in patient ha rm. Whereas 
overdoses and underdoses constitute medication errors, doses missed inadvertent ly by 
a pati ent do not. Individuals who identify a potential medicat ion error (including 
overdose) situation should immediately report this via the phone numbers or e-mail 
address provided below.
[Tabl e of contact informat ion]
Product complaints in and of themselves are not AEs. If a product complaint results in 
an SAE, an SAE Form should be completed and sent to Cognizant (refer to Section 
10.2).
Amended 
or new 
wording:A product complaint is a verbal, written, or electronic expression that implies 
dissatisfaction regarding the ident ity, strength, puri ty, quali ty, or s tabilit y of a drug 
product. Individuals who ident ify a potential product complaint situation should 
immed iately report this via the phone numbers or e mail addresses provided below to: 
ctmcomplaint@takeda.com .
Product complaints in and of themselves are not AEs. If a product complaint 
results in an SAE, an SAE Form should be completed and sent to Cognizant 
(refer to Section 10.2).
A medicat ion error is a preventable event that involves an ident ifiable pat ient and that 
leads to i nappropri ate medicat ion use, which may  resul t in patient harm. Whereas 
overdoses and underdoses constitute medication errors, dose s missed inadvertent ly by 
a pati ent do not. Individuals who identify a potential medicat ion error (including 
overdose) situation should immediately report this via the phone numbers or e mail 
address provided below to Cognizant ( refer to Section 10.2). 
[Deleted table of contact informat ion]
Product complaints in and of themselves are not AEs. If a product complaint results in 
an SAE, an SAE Form should be completed and sent to Cognizant (refer to Section 
10.2).
Rationale for Change:
To cl arify procedures in this protocol. 
For non-commercial use only
Ixazomib
Study No. C16027 Page 76of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALChange 22:Clarified language regarding qualit y assurance audits and Regulatory  Agency 
inspections.
The change occurs in Sect ion14.3 Qualit y Assurance Audi ts and Regulatory  Agency Inspections : 
Initial 
wording:The study  site also m ay be subject to qualit y assurance audi ts by  the sponsor or 
designees. In this circumstance, the sponsor -designate d auditor will contact the site in 
advance to arrange an audit ing visit. 
Amended 
or new 
wording:The study  site also m ay be subject to qualit y assurance audi ts by  the sponsor or 
designees. In this circumstance The investigator agrees to provide access to 
records, facilities, and personnel for conduct of any inspection or audit. If a 
quality assurance audit is requested , the sponsor -designated auditor will contact the 
site in advance to arrange an audit ing visit.
Rationale for Change:
To cl arify procedures in this protocol. 
Change 23:Add informat ion about alternat ive mo nitoring approaches, such as remote source data 
verification, in the event a monitor cannot visit the site in a timely manner due to the COVID -19 
pandemic.
The change occurs in Sect ion 14.1 Study -Site Monitoring Visi ts: 
Added text: In the event a monitor cannot visit the site in a timely manner due to the 
COVID -19 pandemic, alternative monitoring approaches such as remote source 
data verification (SDV) or telephone contact may be used to ensure data quality 
and integrity and maintain patient safety. Alternative monitoring approaches 
should be used only where allowed by the local Health Authority a nd permitted 
by the IRB/IEC.
Rationale for Change:
To cl arify rem ote source data verification procedures to account for the COVID -19 pandemic.
Change 24:Clarify the ixazo mib capsul e strengths that are available.
Theprimary change occurs in Section 8.9Descriptio n of Invest igational Agents : 
Initial 
wording:The ixazo mib capsule formulat ion consists of the drug substance (ixazomib citrate), 
microcrystalline cellulo se, tal c, and magnesium stearate. There are 6 capsule 
strengths: 0.2, 0.5, 2.0, 2.3, 3.0, and 4.0 mg. Each strength is different iated by a unique 
capsule size and color. Dosage strength is stated as ixazo mib. Ixazomib capsules are 
individually  packaged in blisters.
For addi tional details, pl ease see the ixazo mib IB and Pharmacy Manual.
Amended 
or new The ixazo mib capsule formulat ion consists of the drug substance (ixazomib citrate), 
microcrystalline cellulo se, tal c, and magnesium stearate. There are 6 7capsule 
For non-commercial use only
Ixazomib
Study No. C16027 Page 77of 77
Protocol Incorporating Amendment No. 03 03 June 2021
CONFIDENTIALwording: strengths: 0.2, 0.5, 2.0, 2.3, 3.0, and4.0, and 5.5 mg. Each strength is different iated by 
a unique capsule size and co lor. Dosage strength is stated as ixazo mib. Ixazo mib 
capsules are individually packaged in blisters.
For addi tional details, pl ease see the ixazo mib IB and Pharmacy Manual.
Secti on 8.10 Preparation, Reconst itution, and Dispensat ionalso contains this change.
Rationale for Change:
To cl arify that capsule strength 5.5 mg is available.
For non-commercial use only
For non-commercial use only